

-1-

Attorney Docket No. 02868-20554WO01

TITLE

MENINGOCOCCAL MULTIVALENT NATIVE OUTER MEMBRANE VESICLE VACCINE,
METHODS OF MAKING AND USE THEREOF

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to the U.S. Provisional Application Number 61/057,462 entitled "Meningococcal Multivalent Native Outer Membrane Vesicle Vaccine" filed May 30, 2008. The entire disclosure and contents of the above application is hereby incorporated by reference in its entirety.

FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0002] The U.S. Government has rights in this invention.

BACKGROUND OF THE INVENTION

[0003] *Neisseria meningitidis* is a major cause of meningitis and septicemia world-wide. Meningococcal meningitis is an inflammation of the meninges, the membrane lining the brain and the spinal cord. In both meningococcal septicemia and meningococcal meningitis, damage is caused by an uncontrolled localized or systemic host inflammatory response. Group B meningococcal disease currently accounts for at least one half of all meningococcal disease in many countries including North and South America, and Europe. The emergence of a new virulent clone of group B *Neisseria meningitidis*, known as ET5, in Norway in the late 70's has since been responsible for prolonged epidemics in Norway, Cuba, Brazil, and Chile. These epidemics have created serious public health problems and led to intensive efforts to develop an effective group B vaccine in several of the affected countries. The absence of a U.S.-licensed group B vaccine along with the poor performance of the A and C capsular polysaccharide vaccines in children under 18 months have prevented serious consideration of routine childhood vaccination against meningococcal disease.

[0004] *Neisseria meningitidis* is divided into 13 serogroups, of which 9 cause invasive disease (A, B, C (C1, C1-), X, Y, W-135, Z, and L). Five the serotypes are targeted for development of vaccines due to their ability to cause epidemics, including serotypes A, B, C, Y and W135 which are the target of much vaccine research.

[0005] Vaccines against serogroups A, C, Y and W135 of *Neisseria meningitidis* that cause nearly all invasive meningococcal disease are available and are routinely used with excellent results. A suitable vaccine against group B strains of *Neisseria meningitidis* has been more difficult to develop

-2-

for a variety of reasons. For instance, the capsular polysaccharide which defines the serogroup is ineffective and potentially unsafe for use in a vaccine because it has the same structure as polysialic acid found on certain human cells, specifically blood cells.

[0006] Further adding to the lack of a suitable vaccine is the fact that subcapsular antigens that are surface exposed, such as outer membrane proteins and the lipooligosaccharide (endotoxin), are antigenically variable and/or inconsistently expressed among group B strains. No single antigen has been identified that alone has all the characteristics that are essential for an effective vaccine.

BRIEF SUMMARY OF THE DISCLOSURE

[0007] In one aspect, the present technology provides a vaccine comprising native outer membrane vesicles (NOMVs) obtained from at least two meningococcal strains that have been genetically modified to provide broad based protection. The native outer membrane vesicles include three different sets of antigens based on PorA, LOS, and conserved outer membrane proteins; and the genetically modified strains have been modified to provide enhanced safety based on inactivation of *lpxLl*, *synX*, and *lgtA* genes. The two meningococcal strains can both express LOS having a different LOS core structure and has an alpha chains consisting of glucose and galactose. Each strain may express at least two different PorA subtype proteins or subtype epitopes which are chosen based on the most prevalent of PorA subtypes among group B case isolates. Further, the vaccine may further include a different conserved surface protein with demonstrated capacity to induce bactericidal antibodies is over-expressed in each strain and are taken from the group consisting of FHBP (GNA1870) variants 1, FHBP variants 2, and FHBP variants 3; NadA; App; NspA; TbpA and TbpB.

[0008] In a further aspect, the present technology provides a combination of NOMVs from three genetically modified, antigenically diverse *Neisseria meningitidis* strains. At least one of the stains is selected from (1) H44/76 HOPS-DL which has the following genetic modifications or characteristics: inactivation of the genes *synX*, *lpxLl*, and *lgtA*; insertion of a second *porA* gene (subtype P1.7-1,1) in the place of *opaD*; increased expression of NadA; and stabilized high expression of Opc and PorA; (2) 8570 HOPS-G_AL which has the following genetic modifications or characteristics: inactivation of the genes *synX*, *lpxLl*, and *lgtA*; insertion of a second *porA* gene in place of *opaD*; increased expression of factor H binding protein variant 1; and stabilized high expression of PorA and Opc; and/or (3) B16B6 HPS-G₂A which has the following genetic modifications or characteristics: inactivation of the genes *synX*, *lpxL 1*, and *lgtA*; insertion of a second *porA* gene in place of *opaD*; increased expression of factor H binding protein variant 2; and stabilized high expression of PorA and Opc. The NOMV are prepared without exposure to detergent

or denaturing solvents from packed cells or from spent culture medium. The vaccine may be combined with one or more adjuvants and may be administered intramuscularly and/or intranasally.

[0009] In another aspect, the present technology provides a vaccine composition against meningococcal disease, more preferably group B meningococcal disease, including native outer membrane vesicles (NOMVs) from one or more genetically modified strains of *Neisseria meningitidis*. The one or more genetically modified strains has been modified by: inactivation of the *synX* gene, inactivation of the *lpxL1* gene, inactivation of the *lgtA* gene in each strain resulting in expression of a shortened or truncated lipooligosaccharides (LOS) that lacks lacto-N-neotetraose tetrasaccharide, and/or insertion of at least one second antigenically different *porA* gene in place of the *opa* gene. In another aspect, the genetically modified strain further comprises increased or stable expression of at least one minor conserved outer membrane protein, and/or stabilized expression of at least one outer membrane protein. The at least one second antigenically different *porA* gene may express at least one PorA subtype protein or subtype epitope selected from the most prevalent of PorA subtypes of meningitidis group B isolates.

[0009a] In another aspect, there is provided the use of a vaccine as defined above in the manufacture of a medicament for immunization against meningococcal disease, wherein said vaccine is to be administered intramuscularly or intranasally.

[0009b] In yet another aspect, there is provided the use of a vaccine as defined above in the manufacture of a medicament for immunization against group B meningococcal disease, wherein said vaccine is to be administered intramuscularly or intranasally.

[0010] In yet another aspect, the present technology provides a genetically modified vaccine strain of *Neisseria meningitidis* subtype B strain. The genetically modified vaccine strain may include H44/76 HOPS-D strain (B1), 8570 HOS-G1 strain (B2), and/or B16B6 HPS-G₂A strain (B3).

[0011] In yet another aspect, the present technology provides a genetically modified vaccine strain of *Neisseria meningitidis* subtype B derived from: H44/76 strain comprising the genetic modifications of i) inactivation of a *synX* gene, ii) inactivation of the *lpxL1* gene, iii) inactivation of the *lgtA* gene, iv) insertion of a second *porA* gene in the place of a *opaD* gene, v) increased expression of NadA compared with the native strain, and vi) stabilized increased expression of Opc and PorA proteins. In some aspects, the genetically modified strain was derived from the ET-5 wild type strain H44/76 (B:15: P1.7,16: L3,7:P5.5,C).

[0012] In another aspect, the present technology provides a genetically modified vaccine strain of *Neisseria meningitidis* subtype B strain: derived from 8570 comprising the genetic modifications of: i) inactivation of a *synX* gene, ii) inactivation of the *lpxL1* gene, iii) inactivation of the *lgtA* gene, iv) insertion of a second *porA* gene in place of *opaD*; v) increased expression of factor H binding protein variant 1; and vi) stabilized increased expression of PorA and Opc proteins. In some aspects, the genetically modified strain was derived from the ET-5 wild type strain 8570 (B:4: P 1.19,15: L3,7v: P5.5,11,C).

-4-

[0013] In yet another aspect, the present technology provides a genetically modified vaccine strain of *Neisseria meningitidis* subtype B derived from B16B6 comprising the genetic modifications of: i) inactivation of a *synX* gene, ii) inactivation of the *lpxL1* gene, iii) inactivation of the *lgtA* gene, iv) insertion of a second *porA* gene (subtype P1.22-1,4) in place of *opaD*; v) increased expression of factor H binding protein variant 2; and vi) stabilized increased expression of PorA and Opc proteins. In some aspects, the genetically modified strain is derived from the ET-37 wild type strain B16B6 (B:2a:P 1.5,2; L2:P5.1,2,5).

[0014] In some aspects, the present technology provides a genetically modified strain grown in iron deficient medium.

[0015] In other aspects, the present technology provides a genetically modified strain wherein inactivation of *synX* gene, *lpxL1* gene, or *lgtA* gene is by an insertion of a drug resistance gene within the sequence of the inactivated gene.

[0016] Yet another aspect provides a vaccine including NOMVs derived from the genetically modified strains of the present technology. The NOMV are prepared from packed cells or spent culture medium without exposure to a detergent or denaturing solvent. The vaccine may further comprise one or more adjuvants. In further aspects, the genetically altered strain is altered to express iron uptake proteins.

[0017] In a further aspect, the present technology provides a vaccine against meningococcal disease comprising a variety of native outer membrane vesicles (NOMVs), wherein at least some of the NOMVs are essentially free of expression or sialylation of lipooligosaccharide (LOS), contain LOS that includes a lipid A with a penta-acyl structure and contain increased expression levels of at least one minor conserved outer membrane protein, wherein the minor conserved outer membrane protein is selected from proteins that induce bactericidal antibodies. The minor conserved outer membrane protein can be selected from the group consisting of NadA, factor H binding protein (FHBP) variant 1, and FHBP variant 2. In other aspects, at least some of the NOMV comprise shortened or truncated LOS that are essentially free of lacto-N-neotetraose (LNnT) tetrasaccharide and/or at least some of the NOMV comprise two or more different PorA proteins.

[0018] In another aspect, the present technology provides a method of eliciting an immune response to meningococcal disease in an animal or human comprising administering the composition containing NOMVs from at least one genetically altered strain of *N. Meningitidis* to the animal or human for immunization against meningococcal disease. The vaccine is used for immunization against group B meningococcal disease.

[0018a] In yet another aspect, there is provided the use of the composition as defined above in the preparation of a medicament for eliciting an immune response to meningococcal disease.

-5-

[0019] In a further aspect, the present technology provides a method of preparing a genetically modified strain of *N. meningitidis* for use in a vaccine against meningococcal disease comprising the steps of: a) selecting a strain of meningococcal type B able to be genetically modified; b) genetically modifying the strain by inactivating the *synX* gene, c) genetically modifying the strain by inactivating the *lpxL1* gene, d) genetically modifying the strain by inactivating the *lgtA* gene, and e) genetically modifying the strain by increasing expression of one or more minor conserved outer membrane proteins. In further aspects, the method further comprises genetically modifying the strain by inserting at least one second antigenically different *porA* gene into the open reading frame of the *opa* gene. In other aspects, the method further comprises the step of genetically modifying the strain to stably express or over express at least one outer membrane protein by replacing the poly-C sequence within the promoter or open reading frame of the at least one outer membrane protein with a sequence containing G and C nucleotides.

[0020] In yet another aspect, the present technology provides a method of preparing a vaccine against meningococcal disease comprising the steps of: a) culturing a genetically modified strain of *N. meningitidis* comprising one or more modification selected from the group consisting of inactivation of the *synX* gene, inactivation of the *lpxL1* gene, inactivation of the *lgtA* gene, insertion of at least one second antigenically different *porA* gene in place of the *opa* gene, increased or stable expression of at least one minor conserved outer membrane protein, and/or stabilized expression of at least one outer membrane protein; b) expanding the culture by fermentation using the cultured strain of a) to inoculate medium in a fermentor; c) inactivating the fermented culture; d) harvesting *N. meningitidis* cultured cells by continuous flow centrifugation and collecting cell paste; e) isolating NOMVs from the cell paste; and f) resuspending NOMVs in buffer or carrier suitable for vaccine administration.

BRIEF DESCRIPTION OF SEVERAL VIEWS OF THE DRAWINGS

[0021] Figure 1 is a flow chart depicting the preparation of a master cell bank of cells for the genetically modified strains of *Neisseria* for vaccine production.

[0022] Figure 2 is a flow chart depicting the production of the cell bank preparation used for making the genetically modified strains of *Neisseria* for vaccine production.

[0023] Figure 3 is a flow chart depicting the fermentation of the *Neisseria* used for making the genetically modified strains of *Neisseria* for vaccine production.

[0024] Figure 4 is a flow chart depicting the purification of NOMVs from the genetically modified strains of *Neisseria* for vaccine production.

-6-

[0025] Figure 5 is a continuation of the flow chart from Figure 4.

[0026] Figure 6 is a picture of a coomassie blue stained gel showing the protein content of standard marker (lane 1), control 8570 HOPS-G NOMV preparation (lane 2), filtered bulk vaccine (lane 3) and final product vaccine (lane 4).

[0027] Figure 7 is a silver stained gel showing lipooligosaccharide content of the vaccine. Lane 1 is the control ML5 LPS, lane 2 is the filtered bulk vaccine and lane 3 is the final vaccine product. Fifteen μ l of a 1:2 dilution of 100 μ g/ml of the vaccine were run on the gel (20 μ l of 100 μ l/ml of 1:2 dilution of control).

[0028] Figure 8 is a picture of an antibody stained western blot showing the identity and composition of the proteins found in the 8570 HOPS-G NOMV vaccine.

[0029] Figure 9 is a graph depicting the TNF- α released from human blood after incubation with different concentrations of the vaccine.

[0030] Figure 10 is a graph depicting IL-6 release from human blood following incubation with different concentrations of the genetically modified NOMV vaccine.

[0031] Figure 11 is a graph depicting the TNF- α released from human blood after incubation with different concentrations of the genetically modified vaccine as compared with DOC-extracted OMV from strain 44/76.

[0032] Figure 12 is a bar graph depicting the bactericidal titers of mice vaccinated with different concentrations of the 8570 HOPS-G Vaccine with or without an adjuvant.

[0033] Figure 13 is a bar graph depicting the bactericidal titer of mice vaccinated with 8570 HOPS-G Vaccine against different test strains.

[0034] Figure 14 is a graph depicting the results of the bactericidal antibody depletion assay for LOS, GNA1870, NOMV and Opc antigens.

[0035] Figure 15 depicts the antibody response of rabbits vaccinated with the 8570 HOPS-G NOMV vaccine with and without adjuvant.

[0036] Figure 16 is a graph depicting the results of an bactericidal depletion assay for test strains against the 8570 HOPS-G1 NOMV vaccine.

[0037] Figure 17 is a graph depicting the results of the bactericidal depletion assay for LOS and FHBP antigens for the the 8570 HOPS-G1 PorA knockout strain.

-7-

[0038] Figure 18 is a representation of phenotype of the three genetically modified strains of *Neisseria* (A=B1, B=B2, and C=B3) of the present technology.

[0039] Figure 19 is a representation of the plasmids used to construct the genetically modified strains of *Neisseria*: a) plasmid constructed to knockout *lgtA*, b) plasmid to express second PorA, c) plasmid to overexpress fHbp driven by orthologous (Ptac if *E. coli*) promoter, and d) plasmid to overexpress NadA driven by a homologous promoter (PorA promoter of *N. meningitidis*) and the e) representational scheme of transformation of *N. meningitidis* with fHbp (variant 1 and 2) and NadA overexpression plasmid via homologous recombination replacing *NspA* gene.

[0040] Figure 20a is depiction of the stabilization of the truncated LOS immunotype of NOMV vaccine strain by knockout of the *lgtA* gene of the three genetically modified strains. Figure 20b is an picture of an immunoblot of the expression of LOS alpha chain by the genetically altered strain B2 and the parental strain (B16B6) with monoclonal antibodies against L3, 7,9 (left) and L8 (right).

[0041] Figure 21 is a picture representation showing the expression of fHbp variant 2 in the genetically modified strain B3. Figure 21a) shows selection of the strain containing the gentamicin resistance recombinant containing the overexpressed fHbp by immunoblotting and Figure 21b) is a Western Blot using JAR4 monoclonal antibody to fHbp showing increased expression of fHBP.

DETAILED DESCRIPTION OF THE INVENTION

[0042] The present technology provides a broadly protective vaccine composition for use in immunization against meningococcal disease, more preferably *Neisseria meningitidis* subgroup type B. One embodiment of the present technology provides a vaccine composition including native outer membrane vesicles (NOMVs) from at least one, preferably at least two, more preferably at least three genetically modified strains of *Neisseria meningitidis*. Native outer membrane vesicles, also known as blebs, are vesicles formed or derived from fragments of the outer membrane of gram negative bacterium naturally given off during growth and may be obtained from culture medium or from the cells by mild methods that do not use detergents or denaturing solvents. These NOMV typically comprise outer membrane proteins (OMPs), lipids, phospholipids, periplasmic material and lipopolysaccharide (LPS) including lipooligosaccharides. Gram negative bacteria, especially pathogens like *N. meningitidis*, often shed NOMVs during virulent infections in a process known as blebbing. In the present technology, NOMV are vesicles produced from the outer membrane of bacteria without the used of chemical denaturation processes and are produced from the genetically modified strains which are antigenically diverse and have each been genetically modified to improve safety, antigenic stability, and the breadth of the protective immune response.

-8-

[0043] One embodiment of the present invention provides a vaccine composition comprising native outer membrane vesicles (NOMVs) derived from at least two or more genetically modified strains of *N. meningitidis*, preferably at least three different genetically modified strains.

[0044] Some embodiments of the present technology provide antigenically diverse strains of *N. meningitidis*, preferably subtype B which include at least three genetic modifications within the genome of the bacteria, more preferably at least five genetic modifications, more suitable at least six genetic modifications. The genetic modifications can include one or more of the following: 1) inactivation of the *synX* gene, which is essential for sialic acid biosynthesis and results in no capsule expression or sialylation of lipooligosaccharide (LOS); 2) inactivation of the *lpxLI* gene which results in a significantly less toxic LOS having lipid A with a penta-acyl structure; 3) insertion of a second, antigenically different *porA* gene in place of one of the *opa* genes (*OpaC* or *OpaD*); 4) increased expression of at least one minor conserved outer membrane protein, the minor conserved outer membrane protein demonstrating the ability to induce bactericidal antibodies (for example, but not limited to, NadA, factor H binding protein (FHBP) variant 1, and FHBP variant 2); 5) inactivation of the *lgtA* gene in each strain which results in the expression of a shortened or truncated LOS that lacks the lacto-N-neotetraose (LNnT) tetrasaccharide; and/or 6) stabilized expression of certain outer membrane proteins, such as Opc and PorA that are susceptible to phase variation in wild type strains.

[0045] The present technology provides genetically modified strains that provide both increased safety of use and increase the breadth of the protective antibody response to meningococcal disease. In one embodiment, the genetically modified strains provide increased safety by incorporating at least one of the following mutations into the bacterial genome: deletion of the *synX* gene which blocks sialic acid synthesis of capsid and results in the formation of capsule-negative phenotype NOMVs, deletion of the *lpxLI* gene which reduces the endotoxin activity by resulting in a penta-acyl lipid A structure, and/or deletion of the *lgtA* gene which block lacto-N-neotetraose biosynthesis on the lipooligosaccharide (LOS) which stabilized the truncated LOS structure; more preferably the genetically modified strains provide two of these mutations, most preferably the genetically modified strains provide all three of these mutations. In another embodiment of the present technology, the genetically modified strains have an increased breadth of protective antibody response by targeting at least one of three sets of possible protective antigens contained within the NOMVs. The three possible antigens targeted include at least one of the following: PorA protein, at least one conserved minor protein, and/or the LOS core structure, and include any combination

-9-

thereof. In more preferred embodiments, the genetically modified strain targets at least two of the possible protective antigens, most preferably targeting all three of the possible protective antigens.

[0046] In some embodiments of the present technology, the *synX*- mutation (inactivation of the *synX* gene) was inserted into the genetically modified strain by a method as described in U.S. Patent 6,558,677, incorporated by reference herein in its entirety. In brief summary, a pUC19-based plasmid containing the *synX* gene in which 200 bp sequence was replaced by a kanamycin resistance gene is used to transform the genetically modified strain. Kan resistant transformants were selected and tested by PCR for the presence of the disrupted *synX* gene and for the capsule negative phenotype. This *synX*- mutant was constructed based on results and sequence information reported by Swartley and Stephens (Swartley and Stephens (1994) *J. Bacteriol.* 176: 1530-1534) who showed that insertion of a transposon into the *synX* gene led to a capsule negative phenotype. The same or an equivalent mutation can be introduced into any transformable *N. meningitidis* strain. A suitable plasmid for use in transforming meningococci was constructed using the following procedure. Three DNA sequences were pieced together using the splicing by overlap extension (SOE) polymerase chain reaction (PCR) technique (Horton et al. (1989) *Gene* 77: 61-65). The three DNA sequences included, in order beginning at the 5' end, *synXB* bases 67 to 681; the kanamycin resistance gene from pUC4K (Pharmacia LKB Biotech Co.) 671 to 1623; and *synXB* bases 886 to 1589. In addition, at the 5' end, a putative uptake sequence, ACCGTCTGAA, was added by including it at the end of the PCR primer used to amplify the *synXB* 67 to 691 base sequence. The complete construct was amplified by PCR, purified and blunt ligated into pUC19. pUC19 was used to transform *Escherichia coli* DH5 α and selected on LB agar with 50 μ g kanamycin. A kanamycin resistant colony was selected, the DNA extracted, purified, and cut with XbaI. Another copy of the presumptive uptake sequence was ligated into this multiple cloning region site and the resulting plasmid again used to transform *E. coli* DH5 α and kanamycin resistant colonies screened by PCR for presence of the additional uptake sequence. Plasmid DNA was isolated from a selected colony and used as a template for PCR using primers that amplified only the insert part of the plasmid excluding the ampicillin resistance gene which should not be introduced into *N. meningitidis*. The amplified DNA was then purified and used to transform the genetically modified *N. meningitidis* strain. The *synX*(-) mutant of *N. meningitidis* was selected by kanamycin resistance and confirmed by PCR amplification of the modified region.

[0047] In some embodiments of the present invention, the *lpxLI* gene was inactivated in the genetically modified strains to produce a reduced endotoxic LOS expressed on the NOMVs in the vaccine compositions. The lipid A of *N. meningitidis* LOS is normally a hexa-acyl structure and is responsible for the endotoxic properties of the LOS. Two acyl-oxy-acyl linked secondary fatty acids

-10-

present in the lipid A are important for endotoxic activity. The genetically modified strain includes the *lpxL1* mutant as described by van der Ley and co-workers (van der Ley, P., Steeghs, L., Hamstra, H.J., van Hove, J., Zomer, B., and van Alphen, L. Modification of lipid A biosynthesis in *Neisseria meningitidis* *lpxL* mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infection and Immunity 69(10), 5981-5990, 2001.) Deletion of the *lpxL1* gene resulted in expression of normal levels of penta-acyl LOS with greatly reduced endotoxicity as tested by both rabbit pyrogen test and by cytokine release assay using human monocytes from whole blood. Other methods for disrupting the *lpxL1* gene are contemplated in further embodiments of the present technology for use in developing the genetically modified strains.

[0048] In some embodiments, the genetically modified strain contains an insertion of a second, antigenically different *porA* gene in place of one of the *opa* gene (*OpaC* or *OpaD*). The major outer-membrane protein, Porin A or PorA of *Neisseria meningitidis*, is the product of the *porA* gene. PorA has wide antigenic variation and is subject to phase variations to evade immune selective pressure; therefore it is not always cross-protective to other subtypes. To increase the reactivity of the vaccine compositions against different subtypes of PorA, at least one additional *porA* gene is inserted into the *opaC* or *opaD* gene of the genetically altered strain. The PorA serotype selected for insertion is selected based on the most prevalent forms of PorA found in cases of subtype B meningococcal disease. Suitable PorA serotypes include, but are not limited to: P1.7-1, (from strain M1080); P1.22,14 (from strain M4410); P1.22,1,4; or other suitable PorA serotypes as to be understood by one skilled in the art or described in the current literature, for example, as described by Sacchi et al., Diversity and prevalence of PorA types in *Neisseria meningitidis* serogroup B in the United States, 1992-1998, J Infect Dis. 2000 Oct;182(4):1169-76. The second PorA genes may be under control of any suitable strong promoter that provided expression of the PorA protein, for example the PorA promoter from suitable strains, e.g., H44/76 strain. Suitable methods of cloning the *porA* gene into the genetically altered strain would be known to a person skilled in the art, and can include, but is not limited to homologous recombination. For example, the *porA* gene may be PCR amplified from bacterial chromosomal DNA, cloned into a cloning vector and recloned into an appropriately constructed plasmid, for example pUC19, using gene splicing by a modification of the overlap extension PCR technique. This construction plasmid can be introduced into the bacterial genome via homologous recombination such as to replace the *opa* gene. Transformants may be selected by colony blotting with monoclonal antibodies to the Porin. These methods are known to one skilled in the art.

-11-

[0049] In further embodiments of the present technology, the modified strains have stable and/or increased expression of at least one minor outer membrane protein. Suitable minor outer membrane proteins demonstrate the ability to induce bactericidal antibodies (for example, but not limited to, NadA, factor H binding protein (FHBP) variant 1, and FHBP variant 2). Not to be bound by any theory, stabilization and/or increased expression of highly conserved surface exposed minor outer membrane proteins identified through genomic analysis as having potential to induce protective antibodies may lead to an increase in the cross-protective immune response. Suitable conserved minor proteins include, but are not limited to, NadA, FHBP variant 1 and 2, and Opc. Methods of stabilizing and/or overexpression of the minor outer membrane protein (OMP) include use of expression plasmids and homologous recombination, or other suitable methods that are known to one skilled in the art. The minor OMPs can be under a strong promoter, for example, but not limited to the *N. meningitidis* PorA promoter or IPTG-inducible *E. Coli* ptac promoter.

[0050] As described in the examples below, construct plasmids were used to establish increased expression of fHbp 1 and fHbp 2 in the genetically modified strains, where the overexpressed protein appeared properly processed, lipidated, and translocated to the surface of the outer membrane. For example, expression of v.1 under the control of IPTG-inducible *E. coli* Ptac promoter in strain 8570 HOPS-G (B2) was about 4-fold higher than in the parental strain 8570 and expression of v.2 in strain B16B2 HPS-G₂A (B3) was 32-64 fold higher than in the parental strain B16B6 (See Figure 20). Alternatively, an expression system that utilized the PorA promoter could be used to stabilize/overexpress the minor conserved proteins.

[0051] In further embodiments of the present technology, the genetically modified strains include inactivation of the *lgtA* gene which results in the expression of a shortened or truncated LOS that lacks the lacto-N-neotetraose (LNnT) tetrasaccharide.

[0052] An important characteristic of meningococcal LOS is phase-variation, which occurs due to high-frequency mutations in homopolymeric tracts of nucleotide residues in *lgtA* and other neisserial genes. These mutations switch on or off the expression of the *LgtA* transferase which mediates the assembly of the LOS α -chain (altering the configuration of substituents on heptose two). This phase-variable activation of the *lgtA* gene may lead to undesirable elongation of the LOS α -chain resulting in lacto N-neotetraose which has structural similarity to human blood cell antigens. The genetically modified strains of the present technology have the *lgtA* gene knocked out by disrupting the native gene with a antibiotic marker or other suitable marker (for use in screening for alternations in the gene), for example, but not limited to the zeomycin resistance gene. Methods of knocking out the *lgtA* gene are known to one skilled in the art including, but not limited to construct plasmids and

-12-

homologous recombination or transformation. The mutated $\Delta lgtA$ gene was inactive in all modified strains during at least 22 observed passages and this was a stabilized truncated form of the LOS core structure. The deletion of the *lgtA* gene stabilizes the truncated α -core LOS structure, for example, providing the truncated core structures as depicted in Figure 19, wherein three exemplary modified strains are shown, for example the B3 strain contains the L8 alpha chain with the L3 core structure. The genetically modified strains of the preset technology contain specific LOS core structures corresponding to immunotypes L3, L5 and L2 providing stabilized core structures in which an immune response can be mounted, and in the examples below demonstrate truncated L8-like LOS (L8-3, L8-5, and L8-2) which are able to kill wild type strains expressing full length LOS. $\Delta lgtA$ strains are able to elicit antibodies that recognize both the truncated and full-length forms of the LOS structure, without cross-reacting with the lacto-N-neotetraose oligosaccharides found on human blood cells.

[0053] In further embodiments of the present technology, the genetically modified strains of *N. meningitidis* have stabilized expression of outer membrane proteins that are normally susceptible to phase variation in wildtype strains, for example, but not limited to, Opc and PorA. The expression of these proteins can be stabilized by methods known in the art, and include the method of replacing the polymeric repeat sequence in either the promoters or within the reading frame of the gene being stabilized with a non-repeating sequence of optimal length for maximal expression. For example, part of the poly-C or poly-G sequence in the promoter of these genes can be replaced with a sequence of the same length containing both C and G nucleotides, for example, 12 bp poly-G sequence of the promoter of *opcA* (see Seq. ID. No. 1) was replaced with a new sequence of the same length containing both C and G nucleotides and a Not I site (See Seq. ID No. 2, Not I site underlined). In other suitable embodiments, the poly-G sequence in the PorA promoter (for example, see Seq. ID No. 3) can be replaced with a new sequence containing both C and G nucleotides.

[0054] Further embodiments of the present technology provide growth of the vaccine strains in liquid medium containing a low level of iron in order to induce protein expression of proteins involved in uptake of iron, for example transferring binding protein A and B. In some embodiments, the medium used did not contain specific addition of iron chelators such as desferol. One suitable medium is modified from that published by BW Catlin (Catlin BW. (1973) *J. Infect. Dis.* 128: 178-194) by replacing several individual amino acids with 1% casamino acids (certified, Difco Laboratories). The medium contained per liter: 0.4 g NH_4Cl , 0.168 g KCl , 5.85 g NaCl , 1.065 g Na_2HPO_4 , 0.17 g KH_2PO_4 , 0.647 g sodium citrate, 6.25 g sodium lactate (60% syrup), 0.037 g $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$, 0.0013 g $\text{MnSO}_4 \cdot \text{H}_2\text{O}$, 5 g glycerol, 0.02 g cysteine, 10 g casamino acids, 0.616 g

-13-

MgSO₄, and distilled water to one liter. The same iron deficient medium was used for the starter flasks and the final culture flasks or fermenters.

[0055] The vaccine composition of the present technology which include NOMVs from at least three different genetically modified strains of subgroup B can provide three potential levels of protection or three types of antigens that each potentially induce a protective antibody response. The three antigens are the PorA protein (six different PorA subtypes are present in the vaccine, two on each of the three vaccine strains); the lipooligosaccharides (three different LOS core structures are present in the vaccine, one from each strain); and the conserved minor proteins NadA, FHBP variants 1 and 2, and Opc, which have been over expressed in the vaccine strains. Although PorA has a relatively high level of antigenic variation with several hundred different sequence variations having been identified, certain PorA serosubtypes are much more frequently encountered than others and a modest number of different serosubtypes may potentially protect against more than half of group B disease. Having more than one antigen capable of inducing bactericidal antibodies in the vaccine is important because it has been shown that when the surface density of an antigen is low, antibodies to it may not be able to initiate a complement mediated lytic event. But if antibodies to two or more such antigens are present the antibodies can together initiate complement mediated lysis. Genetically modified strains of the present invention include, but are not limited to, the three strains depicted in Figure 18, including B1 (44/76 HOPS-D), B2 (8570 HOPS-G1) and B3 (B16B6 HPS-G2) strains.

[0056] The present technology provides a vaccine that provides broad spectrum protection against meningococcal disease, specifically meningococcal disease caused by *Neisseria meningitidis* subgroup B. The vaccine composition of the present invention can be combined with the existing tetravalent A, C, Y, and W-135 vaccine to provide protection against a majority of pathogenic serogroups of *N. meningitidis*. Not to be bound by any particular theory, the vaccine of the present technology may also provide back up protection against the other pathogenic serogroups as well as the minor serogroups of meningococci since the subcapsular antigens on which it is based are shared across all serogroups of meningococci.

[0057] In preferred embodiments of the present technology, the genes of interest or DNA of interest is delivered and integrated into the bacterial chromosome by means of homologous and/or site specific recombination. Integrative vectors used to deliver such genes and/or operons can be conditionally replicative or suicide plasmids, bacteriophages, transposons, or linear DNA fragments obtained by restriction hydrolysis or PCR amplification as known by one skilled in the art. In some embodiments, integration is targeted to chromosomal regions dispensable for growth in vitro. In other embodiments, the gene of interest or DNA of interest can be delivered to the bacterium by

-14-

means of episomal vectors such as circular/linear replicative plasmids, cosmids, plasmids, lysogenic bacteriophages, or bacterial artificial chromosomes. Selection of recombination events can be selected by means of selectable genetic markers such as genes conferring resistance to antibiotics (e.g., kanamycin, zeomycin, erythromycin, chloramphenicol, gentamycin, etc.), genes conferring resistance to heavy metal and/or toxic compounds or genes complementing auxotrophic mutations. Alternatively, recombination can be screened by PCR amplification, sequencing, restriction digestion or other methods known to one skilled in the art.

[0058] A "vaccine" as referred herein is defined as a pharmaceutical or therapeutic composition used to inoculate an animal in order to immunize the animal against infection by an organism, preferably a pathogenic organism. Vaccines typically comprise one or more antigens derived from one or more organisms which on administration to an animal will stimulate active immunity and protect that animal against infection with these or related pathogenic organisms.

[0059] The purified NOMVs are prepared for administration to mammals, suitably humans, mice, rats or rabbits, by methods known in the art, which can include filtering to sterilize the solution, diluting the solution, adding an adjuvant and stabilizing the solution.

[0060] Vaccines of the present invention may be administered to a human or animal by a number of routes, including but not limited to, for example, parenterally (e.g. intramuscularly, transdermally), intranasally, orally, topically, or other routes known by one skilled in the art. The term parenteral as used hereinafter includes intravenous, subcutaneous, intradermal, intramuscular, intraarterial injection, or infusion techniques. The vaccine may be in the form of a single dose preparation or in multi-dose flasks which can be used for mass vaccination programs. Suitable methods of preparing and using vaccines can be found in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, Pa., Osol (ed.) (1980) and *New Trends in Developments in Vaccines*, Voller et al. (eds.), University Park Press, Baltimore, Md. (1978), incorporated by reference.

[0061] A vaccine composition of the present technology is typically administered parenterally in dosage unit formulations containing standard, well-known nontoxic physiologically acceptable carriers, adjuvants, and/or vehicles.

[0062] The vaccine compositions of the present technology may further comprise one or more adjuvants. An "adjuvant" is a substance that serves to enhance, accelerate, or prolong the antigen-specific immune response of an antigen when used in combination with specific vaccine antigens but do not stimulate an immune response when used alone. Suitable adjuvants include inorganic or organic adjuvants. Suitable inorganic adjuvants include, but are not limited to, for example, an

-15-

aluminium salt such as aluminum hydroxide gel (alum) or aluminium phosphate (preferably aluminium hydroxide), but may also be a salt of calcium (particularly calcium carbonate), iron or zinc, or may be an insoluble suspension of acylated tyrosine, or acylated sugars, cationically or anionically derivised polysaccharides or polyphosphazenes. Other suitable adjuvants are known to one skilled in the art. Suitable Th1 adjuvant systems may also be used, and include, but are not limited to, for example, Monophosphoryl lipid A, other non-toxic derivatives of LPS, and combination of monophosphoryl lipid A, such as 3-de-O-acrylated monophosphoryl lipid A (#D-MPL) together with an aluminium salt.

[0063] Other suitable examples of adjuvants include, but are not limited to, MF59, MPLA, *Mycobacterium tuberculosis*, *Bordetella pertussis*, bacterial lipopolysaccharides, aminoalkyl glucosamine phosphate compounds (AGP), or derivatives or analogs thereof, which are available from Corixa (Hamilton, Mont.), and which are described in U.S. Pat. No. 6,113,918; e.g., 2-[(R)-3-Tetradecanoyloxytetradecanoylamino]ethyl, 2-Deoxy-4-O-phosphono-3-O-[(R)-3-tetradecanoyloxytetradecanoyl]-2-[(R)-3-tetradecanoyloxytetradecanoylamino]-b-D-glucopyranoside, MPL™ (3-O-deacylated monophosphoryl lipid A) (available from Corixa) described in U.S. Pat. No. 4,912,094, synthetic polynucleotides such as oligonucleotides containing a CpG motif (U.S. Pat. No. 6,207,646), COG-ODN (CpG oligodeoxynucleotides), polypeptides, saponins such as Quil A or STIMULON™ QS-21 (Antigenics, Framingham, Mass.), described in U.S. Pat. No. 5,057,540, a pertussis toxin (PT), or an *E. coli* heat-labile toxin (LT), particularly LT-K63, LT-R72, CT-S109, PT-K9/G129; see, e.g., International Patent Publication Nos. WO 93/13302 and WO 92/19265, cholera toxin (either in a wild-type or mutant form). Alternatively, various oil formulations such as stearyl tyrosine (ST, see U.S. Pat. No. 4,258,029), the dipeptide known as MDP, saponin, cholera toxin B subunit (CTB), a heat labile enterotoxin (LT) from *E. coli* (a genetically toxoided mutant LT has been developed), and Emulsomes (Pharmos, LTD., Rehovot, Israel). Various cytokines and lymphokines are suitable for use as adjuvants. One such adjuvant is granulocyte-macrophage colony stimulating factor (GM-CSF), which has a nucleotide sequence as described in U.S. Pat. No. 5,078,996. The cytokine Interleukin-12 (IL-12) is another adjuvant which is described in U.S. Pat. No. 5,723,127. Other cytokines or lymphokines have been shown to have immune modulating activity, including, but not limited to, the interleukins 1- α , 1- β , 2, 4, 5, 6, 7, 8, 10, 13, 14, 15, 16, 17 and 18, the interferons- α , β and γ , granulocyte colony stimulating factor, and the tumor necrosis factors α and β , and are suitable for use as adjuvants.

[0064] The vaccine compositions can be lyophilized to produce a vaccine against *N. meningitidis* in a dried form for ease in transportation and storage. Further, the vaccine may be prepared in the form of a

-16-

mixed vaccine which contains the NOMVs containing the proteins from the genetically altered strains described above and at least one other antigen as long as the added antigen does not interfere with the effectiveness of the vaccine and the side effects and adverse reactions are not increased additively or synergistically. The vaccine can be associated with chemical moieties which may improve the vaccine's solubility, absorption, biological half life, etc. The moieties may alternatively decrease the toxicity of the vaccine, eliminate or attenuate any undesirable side effect of the vaccine, etc. Moieties capable of mediating such effects are disclosed in *Remington's Pharmaceutical Sciences* (1980). Procedures for coupling such moieties to a molecule are well known in the art.

[0065] The vaccine may be stored in a sealed vial, ampule or the like. The present vaccine can generally be administered in the form of a spray for intranasal administration, or by nose drops, inhalants, swabs on tonsils, or a capsule, liquid, suspension or elixirs for oral administration. In the case where the vaccine is in a dried form, the vaccine is dissolved or suspended in sterilized distilled water before administration. Any inert carrier is preferably used, such as saline, phosphate buffered saline, or any such carrier in which the NOMV vaccine has suitable solubility.

[0066] Vaccine compositions of the present technology may include a carrier. If in a solution or a liquid aerosol suspension, suitable carriers can include, but are not limited to, salt solution, sucrose solution, or other pharmaceutically acceptable buffer solutions. Aerosol solutions may further comprise a surfactant.

[0067] Among the acceptable vehicles and solvents that may be used include water, Ringer's solution, and isotonic sodium chloride solution, including saline solutions buffered with phosphate, lactate, Tris and the like. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium, including, but not limited to, for example, synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

[0068] Injectable preparations, for example sterile injectable aqueous or oleaginous suspensions, are formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation are also a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.

[0069] The presently described technology and its advantages will be better understood by reference to the following examples. These examples are provided to describe specific embodiments of the present technology. By providing these specific examples, the applicants do not limit the scope and spirit of the present technology. It will be understood by those skilled in the art that the full scope of

-17-

the presently described technology encompasses the subject matter defined by the claims appending this specification, and any alterations, modifications, or equivalents of those claims.

EXAMPLES

Example 1: Derivation of the genetically modified vaccine strain of *N. meningitidis* and production of NOMVs containing the outer membrane proteins of the genetically modified vaccine strain.

[0070] The genetically modified strain 8570 HOPS-G1 was modified by five genetic modifications from a parental strain 8570 which had been analyzed by multilocus enzyme electrophoresis by the laboratory from whom the strain was obtained and determined to belong to the ET-5 clonal complex (Caugant, et al.) The PorA variable regions were sequenced typed and the LOS immunotype was verified before the genetic modifications were made. Strain 8570 was and ET-5 clone 4:P1.19, 15:L7v, ProB3 (ST4) Tbp2 type II. A series of five sequential genetic modifications were made to the strain as described below:

[0071] 1) A second, different *porA* gene was inserted at the *opaD* locus knocking out the *opaD* gene. pUC 19-based plasmid pA 18.4 has no antibiotic resistance marker in the insert, was used to insert a second *porA* gene into the chromosome at the *opaD* locus, disabling *opaD* by replacing a 100 bp sequence in the middle of the gene with the insert. The insert contained the new *porA* gene taken from strain M4410 (B:15:PI.22,14) and placed behind a *porA* promoter taken from strain H44/76. The resulting *porA* type was P1.19,15: P1.22,14 containing the two porin A genes.

[0072] 2) Starting with the strain resulting from 1, with a second PorA expressed, the expression of the outer membrane protein OpcA was stabilized by replacing a 12 bp poly-C sequence in the promoter of *opcA* with a new sequence of the same length containing both C and G nucleotides. Original promoter sequence (Seq. ID No. 1) (poly-G sequence italicized and bold) 5'..CATAGTTAAAACCTCTAAAATTTGGATTGTAGTCGGATATGGTAACATAACGTAAATA ATCGTTACGCTTACAATTATATTCTTAAGCTTTCGGGGGGGGGGGGGATTT..3' was replaced with a modified promoter sequence (Seq ID No. 2) containing both G and C nucleotides with a Not I site (underlined)

5'..CATAGTTAAAACCTCTAAAATTTGGATTGTAGTCGGATATGGTAACATAACGTAAATA ATCGTTACGCTTACAATTATATTCTTAAGCTTTCGCGCGCGCGCGCATTTT.3' The replacement sequence was chosen to contain a restriction site for NotI to enable verification of the presence of the replacement sequence. The plasmid used for the transformation was pOpc79 (Seq. ID No. 4). The plasmid insert does not contain an antibiotic marker. Selection of transformants was based on colony blotting with monoclonal antibody to OpcA. The strain to be transformed was chosen

-18-

to be an OpcA negative phase variant, and strong OpcA positive clones were identified by colony blotting. True transformants were distinguished from OpcA positive phase variants by PCR and restriction enzyme (Not I) analysis.

[0073] 3) Starting with the strain resulting from 2, the gene *lpxLl*, which is an acyl transferase responsible for linking one of two acyl-oxy-acyl linked fatty acids to the lipid A of the LOS, was disabled by replacing a 260 bp sequence in the middle of the *lpxLl* gene with an insert containing the tetM antibiotic resistance gene. The tetM gene was obtained from a plasmid pJS1934, which was derived from the transposon Tn916 (Swartley, et al. 1993. Mol. Microbiol. 10:299-310). The plasmid used to disable the *lpxLl* gene was pMn5 (Seq. ID No. 5). The presence of the insert in the *lpxLl* gene was verified by PCR which produced a 3.3 kbp amplicon using primers at the beginning and end of the *lpxLl* gene.

[0074] 4) Starting with the strain resulting from step 3, expression of the conserved outer membrane protein GNA 1870 (variant 1) (FHBP v.1) was increased by inserting a second copy of the GNA 1870 variant 1 gene in the *nspA* locus, knocking out expression of NspA. The newly inserted gene was part of an insert that contained a gentamicin antibiotic resistance gene, the *E. coli lac* operon with the IPTG-inducible Ptac promoter, the GNA1870 variant 1 gene and the *rrnB* terminator, the plasmid used is depicted in Figure 19c and Seq. ID No. 6. The PUC19 based plasmid, pBE/GNA1870/101, was used in the transformation and homologous recombination to insert the GNA 1870 variant 1 gene into the modified strain. pBE/GNA1870/101 plasmid (7687 b.p.) was constructed with the features as described in in Table 1 (sequence can be found in Seq. ID No. 6).

-19-

Table 1

<u>Feature</u>	<u>Coordinates (nt ##)</u>	<u>Source</u>
pUC19 ^{a)}	1-191	New England Biolabs (NEB)
Sac I site (unique)	192-197	pUC19 cloning site
Uptake Sequence	198-212	PCR construct
5' NspA non coding region (NCR)	213-1248	<i>N. mening.</i> , 44-76, PCR construct
Bam H I site	1249-1254	Gent ^R gene cloning site
Gent ^R gene	1255-2104	PCR construct of Gent ^R gene
Sac II (unique)	2105-2110	PCR construct
Rmp promoter 5' fragment (rest)	2111-2230	Previous plasmid for NspA expression
Mfe I site (unique)	2231-2236	PCR construct
<i>Lac</i> ^a operon	2237-3641	pMAL-p2X (New England Biolabs)
Ptac promoter	3642-3673	pMAL-p2X, PCR construct
<i>Lac</i> operator	3674-3702	pMAL-p2X, PCR construct
RBS	3750-3755	pMAL-p2X, PCR construct
Nde I site (unique)	3761-3766	PCR construct
fHBP (variant 1) leader peptide	3764-3823	<i>N. mening.</i> , 44-76, PCR construct
fHBP (variant 1) ORF with stop codon	3824-4588	<i>N. mening.</i> , 44-76, PCR construct
SgrAI site (unique)	4589-4596	<i>N. mening.</i> , 44-76, PCR construct
3'NspA and 3'NspA NCR	4597-4638	Previous plasmid for NspA expression
rrnB transcription terminators	4639-4945	pBAD/Thio-E (Invitrogen), PCR
3' NspA NCR	4946-5432	<i>N. mening.</i> , PCR construct
Uptake Sequence	5433-5447	PCR construct
Hind III	5448-5453	pUC19 cloning site
pUC 19	5454-7687 end	NEB (Amp. ^R)

*) Start from nt. 1 of pUC 19. The plasmid was modified to remove Nde I site for further convenient cloning as follow: It was digested by Nde I - EcoR I and 213 b.p. fragment was removed. Sticky ends were filled in and ligated to restore the plasmid. As a result sites Nde I (183) and EcoRI (395) were destroyed. For cloning of constructs for the expression of target protein we used Sac I and Hind III cloning sites of pUC 19.

[0075] 5) The strain resulting from step 4 was transformed with a pUC19-based plasmid containing the *synX* gene in which a 200 bp sequence was replaced by a kanamycin resistance gene. Kanamycin resistant transformants were selected and tested by PCR for the presence of the disrupted *synX* gene and for the capsule negative phenotype. The results verified the knockout of the *synX* gene.

[0076] 6) The strain resulting from step 4 was transformed with a plasmid pBE-501 containing zeomycin gene knocking out the *lgtA* gene (Seq. ID No. 9). Plasmid pBE-501 contained the features found in Table 2. Knock-out of the *lgtA* gene produced expression of a shortened or truncated LOS that lacks the lacto-N-neotetraose (LNnT) tetrasaccharide (see Figure 20).

-20-

Table 2

<u>Feature</u>	<u>Coordinates (nt #)</u>	<u>Source</u>
pCR 4-TOPO TA cloning Vector	1-3667	Invitrogen. Type: pUC ori
Uptake Sequence	3668-3682	PCR construct
LgtA 5' segment	3683-4037	<i>N. mening.</i> , 2996, PCR construct
pEM7/Zeo	4038-4122	Invitrogen. Cloning site and EM7 promoter Zeocin
	4123-4497	Zeocin ^R gene provided ΔLgtA pEM7/Zeo
	4498-4633	Fragment of pEM7/Zeo cloning site LgtA 3'
segment	4634-5448	<i>N.mening.</i> , 2996, PCR construct
Uptake Sequence	5449-5463	Uptake sequence
pCR 4-TOPO TA cloning Vector	5464-5759 end	Invitrogen

*) LgtA cDNA was digested by BssH II. Resulting 3' and 5' sticky ends were refilled and Zeocin gene was inserted in this blunt ended cDNA. In case of excising of disruptive Zeocin gene which may occur during of the reparation of bacterial DNA, relegated 5' and 3' of LgtA fragments will bearing unreparable sequence

[0077] This genetically modified strain was tested to unsure retention of all five mutations and expression of all expected antigens.

Example 2: Production of Vaccine amounts of the genetically modified strain

[0078] The genetically modified strains were then used for production of master and production cell banks for use in vaccine manufacture as detailed in the flow-charts in Figures 1-5 to produce a composition of NOMVs. The NOMVs culture is tested for the expression of the outer membrane proteins and LOS.

Example 3: Characterization of Vaccines

[0079] The final product obtained from Example 2 was subjected to quality control testing and preclinical safety and immunogenicity testing in mice and rabbits.

[0080] The composition of the final product vaccine was:

Protein 2001 ag/ml
 Lipooligosaccharide 36 tg/ml
 Nucleic Acid 2.5 µg/ml
 Sodium Chloride 0.9%
 Tris-HCl Buffer 0.01 M pH 7.6

[0081] The vaccine composition was further analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis and western blotting. Figure 6 depicts coomassie blue stained gel showing protein content in the vaccine (lane 4) as compared to control (lane 2) and filtered bulk lot (lane 3). Figure 7 depicts silver stain gel showing the liposaccharide component of the vaccine (lane 3) as compared with control (ML5 LPS, land 1) and filtered bulk vaccine lot (lane 2). Figure 8 depicts the results of identity testing of the vaccine for the major components of the NOMVs vaccine according to the antibodies as listed in Table 3.

-21-

Table 3

Lane	Antibody Specificity	Monoclonal Antibody	Expected Reaction	Test Result
1	Pre-stained standard	NA		
2	L8 LOS	2-1 L8	Trace	Trace
3	L8v LOS	25-1-LC1	Positive	Positive
4	L3,7 LOS	9-2-L379	Trace	Trace
5	Lip (H8)	2-1-CA2	Positive	Positive
6	Opa P5.10	23-1-P5.10	Negative	Negative
7	Opa P5.11	MF7-1-P5.11	Negative	Negative
8	Opc (P5.C)	B306-P5C	Positive	Positive
9	FHBP I (GNA1870)	JAR 4	Positive	Positive
10	Rmp	9F5	Positive	Positive
11	PorB P4	15-1-P4	Positive	Positive
12	PorA P1.14	MN21G3.17	Positive	Positive
13	PorA P1.15	MN3C5C	Positive	Positive
14	PorA P1.19	2-1-P1.19	Positive	Positive
15	TBP2	476C2G2	Positive	Positive
16	Gp B Polysaccharide	2-2-B	Negative	Negative
17	Amido Black Stain	NA		

[0082] The results are found in Figures 6, 7 and 8 showing proteins found in the NOMV of the vaccine from the genetically modified strain 8570 HOPS-G NOMV contain the proteins and LOS as described.

Example 4: General Safety Test of the Vaccine

[0083] The vaccine was tested in the General Safety Test as prescribed in 21 CFR 610.11. The results for the vaccine are given in Table 4.

Table 4

Test Article	Test Result	Comments
8570 HOPS-G NOMV Vaccine Lot # 1289	Passed	All animals remained normal and healthy and gained weight

Example 5: Rabbit Pyrogenicity Test*

[0084] The results of the rabbit pyrogen test for endotoxin activity are given in Table 3 for the genetically modified vaccine 8570 HOPS-G NOMV alone and the vaccine adsorbed to aluminum

-22-

hydroxide adjuvant. The values given are the highest amounts tested that did not induce a fever in the rabbits (temperature increase of $> 0.5^{\circ}\text{C}$), results of which are found in Table 5.

Table 5

Test Article	Conc. Tested	Temperature Rise for Indicated Rabbit		
		1	2	3
8570 HOPS-G NOMV Vaccine Lot # 1289	0.4 pg/kg	0.1	0.2	0.2
8570 HOPS-G NOMV Vaccine Lot # 1289 adsorbed to aluminum Rehydrigel HPA lot # 1347	0.5 $\mu\text{g/kg}$	0	0	0

* These tests were performed by BioReliance, Inc. under GLP following the protocol specified in the CFR.

** Amount of aluminum hydroxide/kg that will be used in the human study for all formulations (doses).

[0085] In summary, the vaccine alone passed at 0.4 pg/kg, the aluminum hydroxide adjuvant passed at 15 pg/kg (the largest amount per kg to be used in the clinical study), and the vaccine adsorbed to aluminum hydroxide passed at 0.5 lag/kg but failed at 1.0 pg/kg. Extrapolation of these results on a pg/kg basis suggest the adsorbed vaccine would be non-pyrogenic in humans up to a dose in the range of 25 - 50 μg .

Example 6: Cytokine Release from Whole Human Blood

[0086] The vaccine was tested for endotoxin content by measuring its ability to induce proinflammatory cytokines TNF-alpha and IL-6, from fresh whole human blood. The results are shown in Figures 9 and 10. The data are the mean of 3 (*E. Coli* LPS Standard and NOMV vaccine lot 1119 with *lpxL2* LOS) or 5 (Lot 0832 NOMV with wild type LOS, and Lot 1289 NOMV vaccine with *lpxL1* LOS) tests. The error bars are the standard error of the mean. The concentration of NOMV is based on protein but the *E. Coli* standard LPS is based on LPS by weight. Not to be bound by any particular theory, these results suggest that the current vaccine may have a similar safety profile in human volunteers as was seen with the *lpxL2* LOS containing vaccine (Meningococcal 44/76 MOS 5D NOMV vaccine, Lot # 1119, BB-IND 12687).

[0087] The activity of the 8570 HOPS-G NOMV Vaccine Lot # 1289 was compared to the activity of deoxycholate extracted outer membrane vesicles (OMV). The vesicles were prepared using the basic method described by Fredriksen JH, et al. NIPH Annals, 14:67-80, 1991, except 0.5% deoxycholate

-23-

(DOC) was used through out the procedure rather than using 1.2% DOC to resuspend the ultracentrifuge pellets. The results of this comparison are shown in Figure 11.

Example 7: Immunogenicity in Mice and Bactericidal antibody response

[0088] Mice were given three doses of genetically modified vaccine strain 8570 HOPS-G at four week intervals with or without adsorption to aluminum hydroxide adjuvant (Rehydragel LV). Groups of 10 mice were vaccinated intraperitoneally at 0, 4 and 8 weeks with 0.1, 0.3, 1.0 or 3.0 µg of NOMV, the vaccine groups are listed in Table 6. Serum was taken at 0, 7 and 10 weeks. The sera were tested for bactericidal antibodies against four different strains, the parent of the vaccine strain and several related strains using normal human serum as a source of complement. Pre-vaccination sera were uniformly lacking in bactericidal activity.

Table 6

Vaccine Group	Vaccine amount injected
1	0.1 µg
2	0.3 µg
3	1.0 µg
4	3.0 µg
5	0.1 µg + Rehydragel LV
6	0.3 µg + Rehydragel LV
7	1.0 µg + Rehydragel LV
8	3.0 µg + Rehydragel LV
9	1.0 µg + Rehydragel HPA

[0089] The results obtained with the 10-week sera (three doses of vaccine) are shown in Figure 12 showing the bactericidal titer of the different vaccine groups for the genetically modified stains. Two of the test strains were isogenic with the parent of the vaccine strain. They were derived from the parent strain by replacing the *porA* gene with an alternate *porA* having a different serosubtype specificity. Two of the PorA proteins expressed in these test strains are present in the vaccine (P1.19,15 and P1.22,14), but the third (P1.22-1,4) is not. The fourth strain, 44/76, has a different PorA, a different PorB, and a different LOS core structure as compared to the vaccine strain. Surprisingly different to published studies in which deoxycholate extracted vesicle vaccines show the PorA antigen as typically the dominant antigen, the results of the vaccine of the present technology demonstrates that the majority of the bactericidal activity was not dependent on the serosubtype of the target strain and hence not against PorA.

-24-

[0090] Bactericidal antibodies induced in mice by the 8570 HOPS-G NOMV vaccine do not show serosubtype specificity, but appear mostly independent of serosubtype and serotype (Figure 13). The antibodies killing strain 44/76 were found to be mainly directed against the LOS. Bars are standard error of the mean. The vaccine was administered with and without adsorption to Rehydrigel LV aluminum hydroxide adjuvant.

[0091] Analysis of the specificity of the bactericidal antibody response against the heterologous strain 44/76 was undertaken by depletion of bactericidal activity with different isolated antigens. Post-vaccination mouse serum was diluted to the bactericidal endpoint (~50% killing) and incubated in 96-well microplate wells coated with different concentrations of several antigens. After 4-hrs incubation, the serum was tested for bactericidal activity and the percent removal of bactericidal antibody determined. Purified LOS prepared from the target strain (immunotype L3,7) was able to remove nearly all the antibody. Purified LOS (immunotype L8v) prepared from the vaccine strain was able to remove about 70% of the antibody. The conserved protein GNA1870 (purified, recombinant protein) appeared to remove about 20% of the bactericidal activity, which, not to be bound by any particular theory, may indicate some cooperative killing involving both anti-LOS antibody and anti-GNA1870 antibody as shown in Figure 14.

Example 8: Immunogenicity in Rabbits

[0092] The vaccine was also tested for immunogenicity in rabbits. Groups of four rabbits were vaccinated intramuscularly with different doses of vaccine, with or without adsorption to aluminum hydroxide adjuvant. Three doses were given at six week intervals and blood was drawn two weeks after the last injection. The bactericidal antibody response of the rabbits to four test strains was determined. The test strains included 3 isogenic variants of 8570 expressing different PorA proteins and L3,7v LOS and strain 44/76 which has a heterologous PorA and LOS with a different core structure. PorA proteins P1.19,15 and P1.22,14 were present in the vaccine, but P1.22-1,4 was not. The results of the bactericidal tests are given in Figure 15. Analysis of the cross reactive bactericidal activity toward strain 44/76 was analyzed in the same manner as for the mouse sera and the results were essentially the same. Most of the cross-reactive bactericidal antibodies could be removed by purified LOS homologous to the test strain

Example 9: Preparation and Animal Testing of a Laboratory Lot of the Complete Multivalent NOMV Vaccine.

[0093] In addition to strain 8570 HOPS-G1 which was described in the Examples above, two additional vaccine strains were selected and genetically modified. The first was strain B 16B6 (B:2a:P

-25-

1.5,2:L2). This strain belongs to the genetic group ET-37 and has a class 2 PorB protein and type I transferrin binding protein B. The second was strain 44/76 (B:15:P1.7,16:L3,7), which belongs to the genetic group ET-5 and is representative of the epidemic strain responsible for the group B meningococcal epidemic in Norway in the 1970's and 1980's. It expresses a class 3 PorB protein and type II transferrin binding protein B.

[0094] Strain B16B6 was genetically modified in much the same manner as described for strain 8570 HOPS-G1. Two genes were disabled, *synX* and *lpxLI*, to prevent capsule synthesis and sialylation of LOS and to reduce the toxicity of the LOS. A second *porA* gene (subtype P1.22-4) was inserted in place of the *opaD* gene. Variant 2 of GNA 1870 (FHBP) with the IPTG inducible *E. coli* Ptac promoter, was inserted in place of the *nspA* gene as a second copy using plasmid pBE-201 (Seq. ID. No 7). Plasmid pBE-201 (7687 b.p. for additional expression of FHBP (variant 2)) was constructed with the features as described in Table 7.

Table 7

<u>Feature</u>	<u>Coordinates (nt ##)</u>	<u>Source</u>
pUC 19 ^{*)}	1-191	New England Biolabs (NEB)
Sac I site (unique)	192-197	pUC19
Uptake Sequence	198-212	PCR construct
5' NspA NCR	213-1248	<i>N. mening.</i> , 44-76, PCR construct
Bam H I site	1249-1254	Gent ^r gene cloning site
Gent ^r gene	1255-2104	PCR construct of Gent ^r gene
Sac II (unique)	2105-2110	PCR construct
Rmp promoter 5' fragment (rest)	2111-2230	<i>N. mening.</i> , PCR construct
Mfe I site (unique)	2231-2236	PCR construct
<i>Lac^d</i> operon	2237-3641	pMAL-p2X (New England Biolabs)
Ptac promoter	3642-3673	pMAL-p2X, PCR construct
<i>Lac</i> operator	3674-3702	pMAL-p2X, PCR construct
RBS	3750-3755	pMAL-p2X, PCR construct
Nde I site (unique)	3761-3766	PCR construct
fHBP (variant 2) leader peptide	3764-3823	<i>N. mening.</i> , 2996, PCR construct
fHBP (variant 2) ORF with stop codon	3824-4588	<i>N. mening.</i> , 2996, PCR construct
SgrAI site (unique)	4589-4596	<i>N. mening.</i> , 44-76, PCR construct
3'NspA and 3'NspA NCR	4597-4638	Previous plasmid for NspA expression
rrnB transcription terminators	4639-4945	pBAD/Thio-E (Invitrogen), PCR
3' NspA NCR	4946-5432	<i>N. mening.</i> , PCR construct
Uptake Sequence	5433-5447	PCR construct
Hind III	5448-5453	pUC19 cloning site
pUC 19	5454-7687 end	NEB, (Amp. ^R)

*) Start from nt. 1 of pUC 19. The plasmid was modified to remove Nde I site for further convenient cloning as follow: It was digested by Nde I - EcoRI and 213 b.p. fragment was removed. Sticky ends were filled in and ligated to restore the plasmid. As a result sites Nde I (183) and EcoRI (395) were destroyed. For cloning of constructs for the expression of target protein we used Sac I and Hind III cloning sites of pUC 19.

A phase variant of the resulting strain expressing a truncated alpha chain consisting of glucose and galactose. L2 LOS was selected by colony blotting. The resulting genetically modified strain was designated B16B6 HPS-G2, see Figure 18.

-26-

[0095] Strain 44/76 was also modified genetically in the same pattern as described for strain 8570 HOPS-G1. The two genes, *synX* and *lpxLl*, were disabled by insertion mutagenesis, a second *porA* gene (subtype P1.7-1, 1) was inserted along with its promoter in place of the *opaD* gene, and a second copy of *nadA* was inserted behind a *porA* promoter in place of the *nspA* gene. Plasmid pBE-311 was used for homologous recombination to insert the *NadA* gene, the plasmid 3-11 was constructed with the features as described in Table 8 and the sequence can be found in Seq. ID No. 8.

Table 8

Feature	Coordinates (nt ##)	Source
pUC19 ^{*)}	1-191	New England Biolabs (NEB)
Sac I site (unique)	192-197	pUC19 cloning site
Uptake Sequence	198-212	PCR construct
5' NspA NCR	213-1248	<i>N. mening.</i> , 44-76, PCR construct
Bam H I site	1249-1254	Gent ^t gene cloning site
Gent ^t gene	1255-2104	PCR construct of Gent ^R gene
Sac II (unique)	2105-2110	PCR construct
PorA promoter (44-76) (modified)**	2111-3266	<i>N. mening.</i> , 44-76, PCR construct
Nde I site (unique)	3267-3272	PCR construct
NadA (allele 3) leader peptide	3270-3338	<i>N. mening.</i> , 2996, PCR construct
NadA (allele 3) ORF with stop codon	3339-4487	<i>N. mening.</i> , 2996, PCR construct
SgrAI site (unique)	4488-4495	<i>N. mening.</i> , 44-76, PCR construct
PorA terminator (44-76)	4496-4910	<i>N. mening.</i> , 44-76, PCR construct
Bsm I	4911-4916	PCR construct
3' NspA NCR	4917-5329	<i>N. mening.</i> , PCR construct
Uptake Sequence	5330-5344	PCR construct
Hind III	5345-5350	pUC19 cloning site
pUC 19	5351-7584 end	NEB, (Amp. ^R)

*) Start from nt. 1 of pUC 19. The plasmid was modified to remove Nde I site for further convenient cloning as follow: It was digested by Nde I - EcoR I and 213 b.p. fragment was removed. Sticky ends were filled in and ligated to restore the plasmid. As a result sited Nde I (183) and EcoRI (395) were destroyed. For cloning of constructs for the expression of target protein we used Sac I and Hind III cloning sites of pUC 19.

**) The 14Gs Poly G tract of the 44-76 promoter was modified by replacing with optimal for the expression 11Gs.

[0096] In addition, expression of *OpcA* was stabilized by curing the phase variation associated with its gene. This was done as described for strain 8570 HOPS-G1 by breaking up the poly-G string in its promoter in Example 1. The *lgtA* gene was interrupted as in Example 1 producing a truncated LOS. A phase variant of the resulting strain expressing the L8 immunotype was selected by colony blotting with an L8 specific monoclonal antibody. This genetically modified strain was designated 44/76 HOPS-D as shown in Figure 18. The two additional strains were characterized to confirm stability of all the genetic modifications and stocks of each were frozen down.

Example 10: Preparation of NOMV Vaccine from Strains B16B6 HPS-G2 and 44/76 HOPS-D.

[0097] The three genetically modified strains were used to prepare laboratory lots of NOMV vaccine compositions. The strains were grown in Catlin's modified medium as one liter cultures in Fernbach flasks on a rotary shaker. The cells were harvested by centrifugation, weighed and the cell paste frozen. The cell paste was thawed and used to prepare NOMV following essentially the same

-27-

procedure as described for the clinical lot of vaccine from strain 8570 HOPS-G1 as described in Example 2. The process was scaled down and ultracentrifugation twice at 225,000 x g for 60 min at 2-8°C to remove nucleic acids and all soluble, non-vesicle material.

Example 11: Immunization of Mice with Complete Multivalent Vaccine

[0098] Groups of ten CD-1 mice were vaccinated intraperitoneally with two pg of NOMV vaccine from each genetically modified vaccine strain (6 pg total for the combined vaccine with NOMV from three strains). Three doses were given at 0, 4, and 8 weeks. Blood was drawn pre-vaccination and 2 weeks following the last vaccination (at 10 weeks).

[0099] Sera from individual mice were tested for bactericidal antibodies against the homologous strains, and pooled serum from each group of 10 mice was tested against a panel of 14 heterologous group B strains and 1 group C strain expressing a broad range of different subcapsular antigens.

[00100] The combined multivalent vaccine induced a geometric mean 1:256 titer against each of the three vaccine strains and a 4-fold or greater increase in bactericidal antibodies against 13 of the 15 heterologous strains. Two of the test strains were not killed in spite of having an antigen shared with one of the vaccine strains. The bactericidal titers observed against the panel of strains are given in the Table 9.

Table 9: Bactericidal Titers of Pooled Mouse Sera against a Diverse Panel of Test Strains

Bactericidal Test Strain	Antigens Expressed	Titer of Pooled Serum from Mice Vaccinated with Indicated Vaccine				
		B1 +B2 +B3	B2 + B3	B1	B2	B3
44/76	B:15:PI.7,16:P5.11,C:L3,7	256	256	256	256	1
8570	B:4:PI.19,15:P5.5:L3,7v	256	256	256	256	2
816136	B:2a:PI.5,2:P5.1a:L2	256	256	1	1	256
9162	B:15:PI.7-2,3:P5.10,11:L3,7*	16	16	8	2	1
M1080	B:1,19:PI.1:P5.3:L1,3,7	2	1	1	1	1
3576	B:NT:PI.22-1:L3,7	128	128	4	2	16
8047	B:2b:PI.5,2:L3,4,7	64	128	1	1	128
9547	B:4:PI.4:L1	256	256	128	2	64
531	B:2a:PI.5,2:P5.1a,1b,4,5:L3,7	256	256	256	1	256
7608	B:2b:PI.5,2:P5.2,c:L4	256	128	1	1	128
6940	B:8,19:PI.NT:L1	4	4	1	1	1
1901	B:8,19:PI.NT:P5.C:L1,3,7	256	32	128	1	8
99M	B:2a:PI.2:P5.1a,1b,5:L3,7	512	512	16	8	256
6275	B:2a:PI.2:P5.1a,4,5:L3,7	—	512	32	1	512
126E	C:8,19:PI.5,2:L1:P5.c	256	256	4	2	64
2981	B:8,19:PI.14:L1	32	8	4	64	2
M4720	B:19:PI.22,14:L2	1	1	1	1	1
6557	B:17:PI.14:L1(3,7)	32	16	1	32	16

-28-

[00101] Vaccine Code: B1 = 44/76 HOPS-D NOMV

B2 = 8570 HOS-G1 NOMV

B3 = B16B6 HPS-G2 NOMV

[00102] These results demonstrate the ability of the combined vaccine to induce bactericidal (protective) antibodies against a broad range of group B strains and potentially strains of other serogroups as well.

[00103] Analysis of the bactericidal antibodies using a bactericidal depletion test demonstrated that antibodies to all three sets of antigens were involved in killing at least some of the test strains. In some cases, it appeared that antibodies to more than one antigen were involved and acted together to produce bactericidal activity against a given strain.

[00104] Additional groups of mice were vaccinated with NOMV vaccine prepared from isogenic mutants of strain 8570 HOPS-G1. The mutant strains differed in their expression of PorA. Two mutants expressed a single PorA (one or the other of the two in the multivalent vaccine strain) and the third was a PorA knockout mutant expressing no PorA protein. Bactericidal titers induced by each of the four strains against several different test strains are shown in Table 10.

Table 10

Test Strain	Mutant of 8570 HOPS-G1 from Which NOMV Vaccine Was Prepared			
	8570 (P1.19,15 and P1.22,14)	8570 (P1.19,15)	8570 (P1.22,14)	8570 APorA
8570	256	256	256	256
44/76	256	256	256	256
B16B6	1	1	1	1
3576	2	8	8	8
9547	2	4	4	2
2981	64	1	16	1
6557	32	1	128	1

[00105] For the first five test strains in Table 10, the PorA expression had no effect on the titer of bactericidal antibodies induced by the vaccine. For the last two strain, which both express P1.14, the presence of the P1.14 epitope in the vaccine correlated with the capacity of the respective serum to kill the strain. This demonstrates that antibodies to PorA are involved in the observed killing for some strains. For other strains such as the homologous strain and strain 44/76 other antigens are responsible for most of the bactericidal activity. This was demonstrated by analysis with the bactericidal depletion assay. Results of one such assay are given in Figure 16. The results shown in Figure 17 demonstrate

-29-

that antibodies to LOS and FHBP (GNA1870) were involved in the killing of strain 8570 by antiserum to PorA knockout mutant of 8570 HOPS-G1.

CLAIMS

1. A vaccine comprising native outer membrane vesicles NOMVs obtained from at least two meningococcal strains that have been genetically modified to provide broad based protection, wherein the native outer membrane vesicles include different sets of antigens, wherein the different sets of antigens comprise one or more PorA protein, one or more lipooligosaccharide (LOS), and one or more conserved outer membrane proteins; and wherein the genetically modified strains have been modified to provide enhanced safety based on inactivation of *lpxLl*, *synX*, and *lgtA* genes; and wherein at least one of the genetically modified strains expresses at least two different PorA subtype proteins or subtype epitopes.
2. The vaccine of claim 1 where the LOS expressed by each strain has a different LOS core structure and has an alpha chain consisting of glucose and galactose.
3. The vaccine of claim 1 where each strain expresses at least two different PorA subtype proteins or subtype epitopes which are chosen based on the most prevalent of PorA subtypes among group B case isolates.
4. The vaccine of claim 1 where a different conserved surface protein with demonstrated capacity to induce bactericidal antibodies is over-expressed in each strain and are taken from the group consisting of FHBP variants 1, FHBP variants 2, and FHBP variants 3; NadA; App; NspA; TbpA and TbpB.
5. A combination of NOMVs from three genetically modified, antigenically diverse *Neisseria meningitidis* strains, wherein the three strains comprise:

(1) H44/76 HOPS-DL which has the following genetic modifications or characteristics:

inactivation of the genes *synX*, *lpxLl*, and *lgtA*;

insertion of a second *porA* gene in the place of *opaD*;

increased expression of NadA; and

stabilized high expression of Opc and PorA;

(2) 8570 HOPS-G_AL which has the following genetic modifications or characteristics:

inactivation of the genes *synX*, *lpxLl*, and *lgtA*;

insertion of a second *porA* gene in place of *opaD*;

increased expression of factor H binding protein variant 1; and

stabilized high expression of PorA and Opc; and

(3) B16B6 HPS-G₂A which has the following genetic modifications or characteristics:

inactivation of the genes *synX*, *lpxL 1*, and *lgtA*;

insertion of a second *porA* gene in place of *opaD*;

increased expression of factor H binding protein variant 2; and

stabilized high expression of PorA and Opc.

6. The combination of vaccine strains of claim 5 wherein strain H44/76 HOPS-DL was derived from the ET-5 wild type strain H44/76.
7. The combination of vaccine strains of claim 5 wherein strain 8570 HOPS-G₁L was derived from the ET-5 wild type strain 8570.
8. The combination of vaccine strains of claim 5 wherein strain B16B6 HPS-G₂L is derived from the ET-37 wild type strain B16B6.
9. The vaccine of claim 1 where the NOMV are prepared without exposure to detergent or denaturing solvents from packed cells or from spent culture medium.
10. The vaccine of claim 1 where the vaccine is suspended in 5% glucose as an excipient.
11. The vaccine of claim 1 where the NOMV are combined with one or more adjuvants including aluminum hydroxide or aluminum phosphate, MF 59, CPG-ODN, or MPLA.
12. Use of a vaccine of claim 1 in the manufacture of a medicament for immunization against meningococcal disease, wherein said vaccine is to be administered intramuscularly or intranasally.
13. Use of a vaccine of claim 1 in the manufacture of a medicament for immunization against group B meningococcal disease, wherein said vaccine is to be administered intramuscularly or intranasally.
14. A vaccine composition against meningococcal disease comprising native outer membrane

vesicles (NOMVs) from one or more genetically modified strains of *Neisseria meningitidis*, wherein the one or more genetically modified strains has been modified by:

- i. inactivation of the *synX* gene,
- ii. inactivation of the *lpxL1* gene,
- iii. inactivation of the *lgtA* gene in each strain resulting in expression of a shortened or truncated lipooligosaccharides (LOS) that lacks lacto-N-neotetraose tetrasaccharide, and
- iv. insertion of at least one second antigenically different *porA* gene in place of the *opa* gene.

15. The vaccine composition of claim 14, wherein the genetically modified strain further comprises increased or stable expression of at least one minor conserved outer membrane protein.

16. The vaccine composition of any one of claims 14-15, wherein the genetically modified strain further comprises stabilized expression of at least one outer membrane protein, wherein the outer membrane protein is selected from the group comprising Opc and PorA.

17. The vaccine composition of any of claims 14-16, wherein the at least one second antigenically different *porA* gene expresses at least one PorA subtype protein or subtype epitope selected from the most prevalent of PorA subtypes of meningitidis group B isolates.

18. The vaccine composition of claim 15-17, wherein the at least one minor conserved outer membrane protein is selected from the group consisting of: FHBP variants 1, FHBP variant 2, FHBP variant 3; NadA; App, NspA, TbpA and B.

19. The vaccine of claim 1, wherein at least one of the genetically modified vaccine strain of *Neisseria meningitidis* subtype B strain: comprises H44/76 HOPS-D strain.

20. A genetically modified vaccine strain of *Neisseria meningitidis* subtype B derived from: H44/76 strain comprising the genetic modifications of

- i) inactivation of a *synX* gene,
- ii) inactivation of the *lpxL1* gene,

- iii) inactivation of the *lgtA* gene,
- iv) insertion of a second *porA* gene in the place of a *opaD* gene,
- v) increased expression of NadA compared with the native strain, and
- vi) stabilized increased expression of Opc and PorA proteins.

21. The genetically modified strain of claim 20, wherein strain H44/76 HOPS-DL was derived from the ET-5 wild type strain H44/76 .

22. The vaccine of claim 1, wherein at least one of the genetically modified vaccine strain of *Neisseria meningitidis* subtype B comprises strain: 8570 HOS-G1.

23. A genetically modified vaccine strain of *Neisseria meningitidis* subtype B strain: derived from 8570 comprising the genetic modifications of:

- i) inactivation of a *synX* gene,
- ii) inactivation of the *lpxL1* gene,
- iii) inactivation of the *lgtA* gene,
- iv) insertion of a second *porA* gene in place of *opaD*;
- v) increased expression of factor H binding protein variant 1; and
- vi) stabilized increased expression of PorA and Opc proteins.

24. The genetically modified strain of claim 23, wherein the genetically modified strain was derived from the ET-5 wild type strain 85 70.

25. The vaccine of claim 1, wherein at least one of the genetically modified vaccine strain of *Neisseria meningitidis* subtype B comprises B16B6 HPS-G₂A strain.

26. A genetically modified vaccine strain of *Neisseria meningitidis* subtype B derived from B16B6 comprising the genetic modifications of:

- i) inactivation of a *synX* gene,
- ii) inactivation of the *lpxL1* gene,

- iii) inactivation of the *lgtA* gene,
- iv) insertion of a second *porA* gene in place of *opaD*;
- v) increased expression of factor H binding protein variant 2; and
- vi) stabilized increased expression of PorA and Opc proteins.

27. The genetically modified strain of claim 26, wherein the genetically modified strain is derived from the ET-37 wild type strain B16B6.
28. The genetically modified strain of any one of claims 20, 21, 23, 24, 26 or 27, wherein the strain is grown in iron deficient medium.
29. The genetically modified strain of any one of claims 20, 21, 23, 24, 26, 27 or 28, wherein inactivation of *synX* gene, *lpxL1* gene, or *lgtA* gene is by an insertion of a drug resistance gene within the sequence of the inactivated gene.
30. A vaccine composition comprising NOMV from one or more genetically modified strain of any one of claims 20, 21, 23, 24, or 26-29.
31. The vaccine composition of claim 30, wherein the vaccine composition comprises NOMVs from two or more genetically modified strains.
32. The vaccine composition of claim 30, wherein the vaccine composition comprises NOMVs from three or more genetically modified strains.
33. The vaccine composition of any one of claims 1-18, and 30-32, wherein the NOMV are prepared from packed cells or spent culture medium without exposure to a detergent or denaturing solvent.
34. The vaccine composition of any one of claims 1-18 and 30-32, where the vaccine composition is suspended in 5% glucose as an excipient.
35. The vaccine composition of any one of claims 1-18 and 30-32, where the NOMV are combined with one or more adjuvants.
36. The vaccine composition of any one of claims 1-18 and 30-32, wherein the genetically altered strain is altered to express iron uptake proteins.

37. A vaccine against meningococcal disease comprising a variety of native outer membrane vesicles (NOMVs), wherein at least some of the NOMVs are essentially free of expression or sialylation of lipooligosaccharide (LOS), contain LOS that includes a lipid A with a penta-acyl structure and contain increased expression levels of at least one minor conserved outer membrane protein, wherein the minor conserved outer membrane protein is selected from proteins that induce bactericidal antibodies, wherein at least some of the NOMV comprise two or more different PorA proteins..
38. The vaccine of claim 37, wherein the minor conserved outer membrane protein is selected from the group consisting of NadA, factor H binding protein (FHBP) variant 1, and FHBP variant 2.
39. The vaccine of claim 37, wherein at least some of the NOMV comprise shortened or truncated LOS that are essentially free of lacto-N-neotetraose (LNnT) tetrasaccharide.
40. The vaccine of claim 37, wherein the at least two or more different PorA proteins are selected from the most prevalent strains of *N. meningitidis* subgroup B strains.
41. Use of the composition of any one of claims 1-18 and 30-32 in the preparation of a medicament for eliciting an immune response to meningococcal disease.
42. The use of claim 41, wherein the vaccine is used for immunization against group B meningococcal disease.
43. A method of preparing a genetically modified strain of *N. meningitidis* for use in a vaccine against meningococcal disease comprising the steps of:
- a) selecting a strain of meningococcal type B able to be genetically modified;
 - b) genetically modifying the strain by inactivating the *synX* gene,
 - c) genetically modifying the strain by inactivating the *lpxL1* gene,
 - d) genetically modifying the strain by inactivating the *lgtA* gene, and
 - e) genetically modifying the strain by increasing expression of one or more minor conserved outer membrane proteins, and

f) genetically modifying the strain inserting at least one second antigenically different *porA* gene into the open reading of the *opa* gene.

44. The method of claim 43, further comprising the steps of:

genetically modifying the strain to stably express or over express at least one outer membrane protein by replacing the poly-C sequence within the promoter or open reading frame of the at least one outer membrane protein with a sequence containing G and C nucleotides.

45. A method of preparing a vaccine against meningococcal disease comprising the steps of:

a) culturing a genetically modified strain of *N. meningitidis* comprising one or more modification selected from the group consisting of:

- i. inactivation of the *synX* gene,
- ii. inactivation of the *lpxL1* gene,
- iii. inactivation of the *IgtA* gene,
- iv. insertion of at least one second antigenically different *porA* gene in place of the *opa* gene,
- v. increased or stable expression of at least one minor conserved outer membrane protein, and
- vi. stabilized expression of at least one outer membrane protein;

b) expanding the culture by fermentation using the cultured strain of a) to inoculate medium in a fermentor;

c) inactivating the fermented culture;

d) harvesting *N. meningitidis* cultured cells by continuous flow centrifugation and collecting cell paste;

e) isolating NOMVs from the cell paste; and

f) resuspending NOMVs in buffer or carrier suitable for vaccine administration.

46. The vaccine of claim 3 or 17, where each most prevalent of PorA subtypes among group B case isolates is selected from the group consisting of P1.7-1.1, P1.22,14, and P1.22-1,4.

seqlist
SEQUENCE LISTING

<110> U.S. ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY
Zollinger, Wendell D.
Donets, Mikhail
Schmiel, Deborah
Ionin, Boris
Marques, Ryan
Moran, Elizabeth E.

<120> MENINGOCOCCAL MULTIVALENT NATIVE OUTER MEMBRANE VESICLE VACCINE,
METHODS OF MAKING AND USE THEREOF

<130> 20554W001

<150> 61/057,462
<151> 2008-05-30

<160> 9

<170> PatentIn version 3.5

<210> 1
<211> 108
<212> DNA
<213> Neisseria meningitidis

<220>
<221> misc_feature
<223> promoter region of opca gene of Neisseria meningitidis

<220>
<221> misc_feature
<222> (93)..(104)
<223> poly-G sequence

<400> 1
catagttaaa acctctaaaa ttgggattgt agtcggatat ggtaacataa cgtaaataat 60
cgttacgctt acaattatat tcttaagctt tcgggggggg ggggattt 108

<210> 2
<211> 109
<212> DNA
<213> Artificial Sequence

<220>
<223> promoter region of opca gene of Neisseria meningitidis

<220>
<221> misc_feature
<222> (93)..(104)
<223> replacement sequence for poly-G sequence

<220>
<221> misc_feature
<222> (95)..(102)
<223> Not I restriction site

<400> 2
catagttaaa acctctaaaa ttgggattgt agtcggatat ggtaacataa cgtaaataat 60
cgttacgctt acaattatat tcttaagctt tcgcgcggcc gcgcatttt 109

seqlist

<210> 3
 <211> 38
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> promoter region of PorA of Neisseria meningiditis

<220>
 <221> misc_feature
 <222> (12)..(25)
 <223> poly-G sequence

<400> 3
 ggtttttttg cggggggggg gggggtataa ttgaagac 38

<210> 4
 <211> 2940
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> plasmid pOpc-79 for insertion of sequence into promoter of opc of Neisseria meningiditis

<400> 4
 ctgcagattg ttttttacga cggggaagtt ggcaaagaaa tagcccgcggt aagaaaacag 60
 gataaccacac aacaagccac cgatgatgtt gtagcggata aatttgcat agtgcatttt 120
 ccccataccg gcgacgaagg gggcgaaggt gcggacgatg ggcataaaac gggcaatgat 180
 gatggttttg ccgccgtgtt tttcgtaaaa acggtgggtt ttatcgagat attcacgtcg 240
 gaagatttta gaatcggggg tggcgaacag cctgccgccg aaatatttgc cgacggtaaa 300
 attgagcgcg tcgccgagta tggcggcaag gcttaataat gcaaccatca aatgaatatc 360
 cataccgccc agcgcggcaa tcccgccggc ggcaaacagc agcgaatcgc cgggcagtaa 420
 gggcgtaaca atcaggccgg tttcgcaaaa aacaatcaaa aacagaatcg cataaatcca 480
 cacaccgtat tgcgccgaca gcgcgagcag gtgttggtcg atatggagga tgaagtcgat 540
 ggcggaggca agcacggcgc gttcctaaaa aaacaaaccg cgtattttta ccgattggaa 600
 aaatgccgtc tgaagagttt cagacggcat cggctattca aattcatttc acgtaaaaac 660
 cgcaaaccaa aatagtttgc ggtttggcat tttaaagtac aatgatgatt tcaaatcatc 720
 agaattttat gccgacgcgc aagccgtatt cacgaatact ggttttcggg atggtgagcg 780
 atacgtcgcc actcttggtt gttacactaa actcgccgga ttctttgtaa gtgcgttggt 840
 tgtagaacgg ccccgccctg atgctggcgg attcgcccag ttttttacca atatttgcac 900
 ccaatccaaa gccccagccg ttggtttttt gattgatgtc ttttttgaga ttggtaacgc 960
 cgggtgtttta tttatagcgg gaattgaggt caaatcacac ttcagaccaa gggttgatat 1020
 accagccgtt acccagttgg gaaagcaaat ccgcgtgaac tttggctaac cagactgac 1080
 ggctgctgtg aagcgtatgc ttggtggtt taatgctgtc ttttgaagat tcaaaacca 1140
 agccggcacc cacacggaaa tttaaagaat cacttaacgt ttgggtgtag gtgtagcctg 1200

seqlist						
tgtaaagatc	gatacggttt	tcaggaacgc	cggtgggcag	ttttacattt	ttagtcttac	1260
ccagcttggt	ctcatctggt	tccaaattaa	taatattttt	tttgctgcgc	ccgaaaccgg	1320
cttccaagcg	gatgccttgg	ttggcatcaa	aaggaatatc	agcacgcacg	ctgatgtggt	1380
tggcagcttt	gtgtttttct	ttcaggaaag	cacgagttga	agaaatggaa	gagaggtcgg	1440
tgtggacggt	aaactcatta	gcggtttgaa	gctcttggtc	agcggcggca	gtaccgggtca	1500
gggcaatcat	ggcacatgta	aaaactgttt	ttttcatagt	taaaacctct	aaaatttgga	1560
ttgtagtcgg	atatggtaac	ataacgtaaa	taatcgttac	gcttacaatt	atattcttaa	1620
gctttcgcgc	ggccgcgcat	tttacaata	ttaataaaaa	ttaacaaata	gttatttggt	1680
tacaacgaat	tgttattctc	acttggtttt	ctgtttttta	tgggaatgac	gaaattttag	1740
tttgtgtgta	tttatcgga	aaacagaaac	ccgccgccgt	cattcccgcg	caggcgggaa	1800
tctagaaccc	aacgcgacaa	aaatttatcc	gaagcgacaa	caatcttttc	atcgtcattc	1860
ccgcgcaggg	gggaatctag	aacgtaaaat	ctaaagaaac	cgttttaccc	gataagtttc	1920
cgtgccgaca	aacctagatt	cccgcctgcg	cggaatgac	gggatttttag	gtttctgatt	1980
tcggttttct	gttttaaggg	aatgacgaga	cttgagatgg	cggcatttat	cgggagcaac	2040
tgaaaccacc	ctgccgtcat	tcccgcgaaa	gcgggaatct	aggttcgtcc	ggtttcggtt	2100
atttccgata	gattcctgcc	gcgttggggg	tctggattcc	cgcttgcgcg	ggaatgacgg	2160
gacttttaggt	ttctgttttt	gtttgagacc	tttgcaaaat	tcctttccct	cccgcagacc	2220
gaaacccaaa	cacagggtttt	cggctgtttt	cgccccaaat	accgcctaata	tttaccctaa	2280
tacccctta	atcctccccg	gatacccgat	aatcaggcat	ccgggctgcc	ttttaggcgg	2340
cagcgggcgc	acttaacctg	ttggccgctt	tcaacagggt	caaacacatc	gccttcaggt	2400
ggctttgcgc	actcacttta	atcagtccga	aataggctgc	ccgcgcatag	cggaattttac	2460
ggtgcagcgt	accgaagctc	tgttcgacca	catatagtgg	attaaattta	aaccagtacg	2520
gcgttgccct	gccttgccgt	actatttgta	ctgtctgcgg	cttcgtcgcc	ttgtcctgat	2580
ttaaatttaa	tccactataa	cgggtcttcg	ataaatatcg	gttacgtttg	gtttgcgttt	2640
ccgtcagcgg	acgggtgcgg	caggctttgc	gcataatgcc	gtccaacaac	tgatgttctt	2700
ccagatgttg	ccgggttttc	gcactgtcat	agcctttgtc	ggcatagacg	gtcgtacctt	2760
tgggcagtcc	ttccaacaaa	ggcggcaggt	gtttgcactc	atgggcattg	gcgggggtaa	2820
tgtgcagttt	ctcgatatag	ccttccgcat	cggtacgggt	atgttgtttg	taaccgagtt	2880
tgtagaggcc	gtttttcttg	atccaacggg	catcgctgtc	cttactcggg	gtgggttggc	2940

<210> 5

<211> 3341

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid pMN5 for insertion sequence used for knockout of lpxL1 (also called htrB) gene of *Neisseria meningitidis*

seqlist

<400> 5

ctgcagaaac	cgtattgtct	gcctcgcgga	cgggaaatggc	gggtatcact	tttgcatttg	60
caagcgcggc	aatgcggctc	aatccggtaa	tcgttgccgt	ctgaataccg	aaaaaatcca	120
caaaaaccga	atcgttgctg	ccgaaatcct	gatcgggcag	atacagaaac	ggcgcgctgc	180
ttttgcggaa	ctgtttgacg	agggcgcgca	gcccttcggt	gcgcccagata	aggaagacgt	240
tgtgatagcg	gttgccggcct	ttcaaaatct	gttcgtccaa	tatcttgttt	ttttgatggg	300
aatacatact	gatcagcggg	atatacctgat	taagcgcgta	caccgccatc	tcgaacgcgg	360
tgaagtgcgg	atacaggatg	atgacacgcg	tttgtaatca	tgtactcttt	ttgataaaaa	420
attggagatt	cctttacaaa	tatgctctta	cgtgctatta	tttaagtac	tatttaaaag	480
gagttaataa	atatgcggca	aggtattctt	aaataaaactg	tcaatttgat	agcgggaaca	540
aataattaga	tgtccttttt	taggagggct	tagttttttg	taccagttt	aagaatacct	600
ttatcatgtg	attctaaagt	atccagagaa	tatctgtatg	ctttgtatac	ctatggttat	660
gcataaaaaat	cccagtata	aaagtattta	tcactgggat	ttttatgccc	ttttgggttt	720
ttgaatggag	gaaaaatcaca	tgaaaattat	taatattgga	gttttagctc	atgttgatgc	780
aggaaaaact	accttaacag	aaagcttatt	atataacagt	ggagcgatta	cagaattagg	840
aagcgtggac	aaaggtacaa	cgaggacgga	taatacgctt	ttagaacgtc	agagaggaat	900
tacaattcag	acaggaataa	cctcttttca	gtgggaaaaat	acgaagggtga	acatcataga	960
cacgccagga	catatggatt	tcttagcaga	agtatatcgt	tcattatcag	ttttagatgg	1020
ggcaattcta	ctgatttctg	caaaagatgg	cgtacaagca	caaactcgta	tattgtttca	1080
tgcacttagg	aaaatgggga	ttcccacaat	cttttttatc	aataagattg	accaaaatgg	1140
aattgattta	tcaacggttt	atcaggatat	taaagagaaa	ctttctgccg	aaattgtaat	1200
caaacagaag	gtagaactgt	atcctaatat	gtgtgtgacg	aactttaccg	aatctgaaca	1260
atgggatacg	gtaatagagg	gaaatgatga	ccttttagag	aaatatatgt	ccggtaaatac	1320
attagaagca	ttggaactcg	aacaagagga	aagcataaga	tttcataatt	gttcctgttt	1380
ccctgtttat	cacggaagtg	caaaaaacaa	tatagggatt	gataacctta	tagaagtgat	1440
tacgaataaa	ttttattcat	caacacatcg	aggtccgtct	gaactttgcg	gaaatgtttt	1500
caaaattgaa	tatacaaaaa	aaagacaacg	tcttgcatat	atacgctttt	atagtggagt	1560
actacattta	cgagattcgg	ttagagtatc	agaaaaagaa	aaaataaaag	ttacagaaat	1620
gtatacttca	ataaatgggtg	aattatgtaa	gattgataga	gcttattctg	gagaaattgt	1680
tattttgcaa	aatgagtttt	tgaagttaaa	tagtgttctt	ggagatacaa	aactattgcc	1740
acagagaaaa	agaattgaaa	atccgcattc	tctactacaa	ataactgttg	aaccgagtaa	1800
acctgaacag	agagaaatgt	tgcttgatgc	ccttttgga	atctcagata	gtgatccgct	1860
tctacgatat	tacgtggatt	ctacgacaca	tgaattata	ctttctttct	tagggaaagt	1920
acaaatggaa	gtgattagt	cactgttgca	agaaaagtat	catgtggaga	tagaactaaa	1980
agagcctaca	gtcatttata	tggagagacc	gttaaaaaat	gcagaatata	ccattcacat	2040

seqlist

```

cgaagtgccg ccaaatcctt tctgggcttc cattggttta tctgtatcac cgcttccggt 2100
gggaagtgga atgcagtatg agagctcggt ttctcttgga tacttaaate aatcatttca 2160
aaatgcagtt atggaaggga tacgctatgg ttgcgaacaa ggattatatg gttggaatgt 2220
gacggaatgt aaaatctgtt ttaagtatgg cttatactat agccctgtta gtaccccgagc 2280
agatttttcgg atgcttgctc ctattgtatt ggaacaagtc ttaaaaaaag ctggaacaga 2340
attgttagag ccatacttta gtttttaaat ttatgcgcca caggaatata tttcacgagc 2400
atacaacgat gctcctaaat attgtgcgaa catcgtagac actcaattga aaaataatga 2460
ggtcattctt agtggagaaa tccctgctcg gtgtattcaa gaatatcgta gtgatttaac 2520
tttctttaca aatggacgta gtgtttgttt aacagagtta aaagggtacc atgttactac 2580
cgggtgaacct gtttgccagc cccgtcgtcc aaatagtcgg atagataaag tacgatatat 2640
gttcaataaa ataacttagt gtatttttatg ttgttatata aatatggttt cttgttaaat 2700
aagatgaaat attttttaat aaagatttga attaaagtgt aaaggaggag atagttatta 2760
taaactacaa gtggatattg tgtcctgtat gtggaaataa aacacgatta aagataaggg 2820
aagatactga attaaaaatt cccctctat tgtccgaaat gcagacaaga aaatttaatt 2880
gaaataaagc agttcaaagt aactgtgatt acagagccag acgcaaagac gcagagccga 2940
taaaatgaga ttaatacaat ctatttttta tcggctcttt ccgttatgta tggattcttt 3000
taacgcgtca gaaactgcaa aacatacagt acaaaaaata taaatttcat ctcgatacac 3060
attttctttt cagacggcaa aatacaaatg ccgtctgaaa ctattgaaac ctgccgcgct 3120
tgacctgcat ccccgaagga ttgagtttgg cggcaagccc gtggttgctg aaggcgtggg 3180
tcagcgcgac ggcaagaccg tccgccgat ccggctgggg cgttcccgaa agtcccaaca 3240
tctgcaccac catatgctgc acctgttctt ttgccgcctt gcccttgccg actaccgcct 3300
gtttgacctg ctttcagacg gtccatccat cacactgcag g 3341

```

<210> 6

<211> 7687

<212> DNA

<213> Artificial Sequence

<220>

<223> plasmid pBE-101 for expression of fHBP variant 1 of Neisseria meningitidis

<400> 6

```

tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacgggtca 60
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg 120
ttggcgggtg tcggggctgg ctttaactatg cggcatcaga gcagattgta ctgagagtgc 180
accataaatt cgagctcgac cgtctgaaac ggcggcaaag ccgttaaccc gcgcgttgcc 240
tttaaatggt ggcggcgcca tcacgcggcg gatgggtgaa acttgcaaac ggtttgga 300
aaacagcggg atctgtcgga ttgttgaggg tgcaggcata cggttttgtg tgcgtctgtg 360

```

seq1list						
ccttaagcgt	cggacatttc	cggcggcggc	tgtgccgtct	gaaacgccc	gcgggggatg	420
cggctgcgtt	ttccatcgat	aagcatat	tccggacgcg	ttcggggcgg	gttttcccgg	480
gcggccgccg	atttgtttgc	gcttatatag	tggattaaca	aaaatcagga	caaggcgacg	540
aagccgcaga	cagtacaaat	agtacggaac	cgattcactt	ggtgcttcag	caccttagag	600
aatcgttctc	tttgagctaa	ggcgaggcaa	cgccgtactg	gtttttgtta	atccactata	660
aaaaacactg	cagcaaatcg	tttaaaaaaca	agcgtccttt	ttcggtcggg	cggaatacgg	720
cagggtcggt	ttccagcagg	cctttttgcc	ttgccgtttc	gatttgcgcc	atgattttgg	780
cactcggtac	gcccgtgcgc	tcctgcaaca	tcgcggcggg	tacgccgtcg	gtcaggcgca	840
gggcgttcat	catgaattcg	aacggcaaat	cttcggcagc	gacggttttg	cgttcgacgg	900
cttcactcgg	ttggctttgc	attaaggcga	ggtagtcgtt	ggggtggcgg	cggcggacgg	960
tgcgctcgat	gcggtcggga	taggaaat	tgccgtgcgc	gcccgcgcct	atgcctaaat	1020
aatcgccgaa	ctgccagtag	ttcaaattgt	ggcggcactg	catggctggg	ttcgaaaag	1080
ccgatgtttc	gtagtggaca	aaacccgcgc	cttcagcgc	gccgtgtacc	gcgtcttcga	1140
tgtcgagggc	ggcttcgtct	tgcggaac	ctttcggcgg	cgatatgacc	aacggcgtgt	1200
tcggttccat	cgtcagggtga	tacgcgctga	tgtgggttgc	gcccgtaggg	atcccgaactt	1260
cgctgctgcc	caaggttgcc	gggtgacgca	caccgtggaa	acggatgaag	gcacgaaccc	1320
agttgacata	agcctgttcg	gttcgtaa	tgtaatgcaa	gtagcgtatg	cgctcacgca	1380
actggtccag	aaccttgacc	gaacgcagcg	gtggtaacgg	cgcagtggcg	gttttcatgg	1440
cttgttatga	ctgttttttt	gtacagtcta	tgccctgggc	atccaagcag	caagcgcgtt	1500
acgccgtggg	tcgatgtttg	atgttatgga	gcagcaacga	tgttacgcag	cagcaacgat	1560
gttacgcagc	agggcagtcg	ccctaaaaca	aagttagggtg	gctcaagtat	gggcatcatt	1620
cgcacatgta	ggctcggccc	tgaccaagtc	aaatccatgc	gggctgctct	tgatcttttc	1680
ggtcgtgagt	tcggagacgt	agccacctac	tccaacatc	agccggactc	cgattacctc	1740
gggaacttgc	tccgtagtaa	gacattcatc	gcgcttgctg	ccttcgacca	agaagcggtt	1800
gttggcgctc	tcgcggctta	cgttctgccc	aggtttgagc	agccgcgtag	tgagatctat	1860
atctatgatc	tcgcagtctc	cggcgagcac	cggaggcagg	gcattgccac	cgcgctcatc	1920
aatctcctca	agcatgaggc	caacgcgctt	ggtgcttatg	tgatctacgt	gcaagcagat	1980
tacggtgacg	atcccgcagt	ggctctctat	acaaagttag	gcatacggga	agaagtgatg	2040
cactttgata	tcgacccaag	taccgccacc	taacaattcg	ttcaagccga	gatcggcttc	2100
ccggccgcgg	aatgccgatt	tcttcttcca	gcaatttgat	ttgtttggag	atgccggggtt	2160
gcgaagtaaa	caaggcttcg	gccgcttcgg	aaacgttcag	gttggtgctgg	taaacttcta	2220
aggcgatatt	caattgccga	caccatcgaa	tggtgcaaaa	cctttcgcgg	tatggcatga	2280
tagcgccccg	aagagagtca	attcaggggtg	gtgaatgtga	aaccagtaac	gttatacgat	2340
gtcgagaggt	atgccgggtg	ctcttatcag	accgtttccc	gcgtgggtgaa	ccaggccagc	2400

seqlist						
cacgtttctg	cgaaaacgcg	ggaaaaagtg	gaagcggcga	tggcggagct	gaattacatt	2460
cccaaccgcg	tggcacaaca	actggcgggc	aaacagtcgt	tgctgattgg	cgttgccacc	2520
tccagtcttg	ccctgcacgc	gccgtcgcaa	attgtcgcgg	cgattaaatc	tcgcgccgat	2580
caactgggtg	ccagcgtggt	gggtgcgatg	gtagaacgaa	gcggcgtcga	agcctgtaaa	2640
gcggcggtgc	acaatcttct	cgcgcaacgc	gtcagtgggc	tgatcattaa	ctatccgctg	2700
gatgaccagg	atgccattgc	tgtggaagct	gcctgcacta	atgttccggc	gttatttctt	2760
gatgtctctg	accagacacc	catcaacagt	attattttct	cccatgaaga	cggtacgcga	2820
ctgggcgtgg	agcatctggt	cgcattgggt	caccagcaaa	tcgcgctggt	agcggggcca	2880
ttaagtcttg	tctcggcgcg	tctgcgtctg	gctggctggc	ataaatatct	cactcgcaat	2940
caaattcagc	cgatagcgga	acgggaaggc	gactggagtg	ccatgtccgg	ttttcaacaa	3000
accatgcaaa	tgctgaatga	gggcatcggt	cccactgcga	tgctggttgc	caacgatcag	3060
atggcgctgg	gcgcaatgcg	cgccattacc	gagtccgggc	tgcgcgttgg	tgcggatatc	3120
tcggtagtgg	gatacgacga	taccgaagac	agctcatgtt	atatcccgcc	gttaaccacc	3180
atcaaacagg	attttcgcct	gctggggcaa	accagcgtgg	accgcttgct	gcaactctct	3240
cagggccagg	cggtgaaggg	caatcagctg	ttgcccgtct	cactggtgaa	aagaaaaacc	3300
accctggcgc	ccaatacgca	aaccgcctct	ccccgcgcgt	tggccgattc	attaatgcag	3360
ctggcacgac	aggtttcccg	actggaaaagc	gggcagtgag	cgcaacgcaa	ttaatgtaag	3420
ttagctcact	cattaggcac	aattctcatg	tttgacagct	tatcatcgac	tgacgggtgc	3480
accaatgctt	ctggcgtcag	gcagccatcg	gaagctgtgg	tatggctgtg	caggtcgtaa	3540
atcactgcat	aattcgtgtc	gctcaaggcg	cactcccgtt	ctggataatg	ttttttgcgc	3600
cgacatcata	acggttcttg	caaataattct	gaaatgagct	gttgacaatt	aatcatcggc	3660
tcgtataatg	tgtggaattg	tgagcggata	acaatttcac	acaggaaaca	gccagtccgt	3720
ttaggtgttt	tcacgagcac	ttcaccaaca	aggaccatag	catatgaatc	gaactgcctt	3780
ctgctgcctt	tctctgacca	ctgccccgat	tctgaccgcc	tgacgcagcg	gaggggggtg	3840
tgtcgccgcc	gacatcgggtg	cggggccttg	cgatgcacta	accgcaccgc	tcgaccataa	3900
agacaaagg	ttgcagtctt	tgacgctgga	tcagtccgtc	aggaaaaacg	agaaactgaa	3960
gctggcggca	caaggtgcgg	aaaaaactta	tggaaacgg	gacagcctca	atacgggcaa	4020
attgaagaac	gacaagggtca	gccgtttcga	ctttatccgc	caaatcgaag	tggacgggca	4080
gctcattacc	ttggagagtg	gagagttcca	agtatacaaa	caaagccatt	ccgccttaac	4140
cgcttttcag	accgagcaaa	tacaagattc	ggagcattcc	gggaagatgg	ttgcgaaacg	4200
ccagttcaga	atcggcgaca	tagcgggcga	acatacatct	tttgacaagc	ttcccgaagg	4260
cggcagggcg	acatatcgcg	ggacggcggt	cggttcagac	gatgccggcg	gaaaactgac	4320
ctacaccata	gatttcgccg	ccaagcaggg	aaacggcaaa	atcgaacatt	tgaaatcgcc	4380
agaactcaat	gtcgacctgg	ccgccgccga	tatcaagccg	gatggaaaac	gccatgccgt	4440

seq1list						
catcagcggg	tccgtccttt	acaaccaagc	cgagaaaagg	agttactccc	tcggtatctt	4500
tggcggaaaa	gcccgaggaag	ttgccggcag	cgcggaagtg	aaaaccgtaa	acggcatacg	4560
ccatatcggc	cttgccgcca	agcaataacg	ccggtgtgcg	cgtcaaattc	tgatatgcgc	4620
cttattctgc	aaaccgccag	cttggctgtt	ttggcggatg	agagaagatt	ttcagcctga	4680
tacagattaa	atcagaacgc	agaagcggtc	tgataaaaca	gaatttgcct	ggcggcagta	4740
gcgcggtggg	cccacctgac	cccatgccga	actcagaagt	gaaacgccgt	agcgccgatg	4800
gtagtggtggg	gtctcccat	gcgagagtag	ggaactgcc	ggcatcaa	aaaacgaaag	4860
gctcagtcga	aagactgggc	ctttcgtttt	atctgttgtt	tgctcggtga	cgctctcctg	4920
agtaggacaa	atccgccgcc	cgggcgagcc	ttcggcgggt	ttgttttctg	ccaccgcaac	4980
tacacaagcc	ggcggttttg	tacgataatc	ccgaatgctg	cggcttctgc	cgccctat	5040
tttgaggaat	ccgaaatgtc	caaaaccatc	atccacaccg	acaaagcccc	cgccgccatc	5100
ggcgcgtaca	gccaagccgt	ccgagcaggc	gacaccgttt	acatgagcgg	tcaa	5160
ctcgatcccc	ccacgatgac	cgtcgtcggc	aacggcgatt	tccgcgccga	agcgcgccaa	5220
gtgttccaaa	acctgcaagc	cgtcgccgaa	gcggcgaggc	gcacgctggc	cgacatcgtc	5280
aaactcaacg	cctacctgac	cgacttgggc	aattttgccg	tcttcaacga	agtcatggcg	5340
gaatttatcg	ccgagccctt	ccccgcccgc	gccgccgtcg	gcgttgccctc	gctgccccaa	5400
ggcgtgcagg	tcgaagccga	agccgtcctc	gtgaccgtct	gaaacggaag	cttggcgtaa	5460
tcatggtcat	agctgtttcc	tgtgtgaaat	tgttatccgc	tcacaattcc	acacaacata	5520
cgagccggaa	gcataaagt	taaagcctgg	ggtgccta	gagtgagcta	actcacatta	5580
attgcgttgc	gctcactgcc	cgctttccag	tcgggaaacc	tgctcgtgcca	gctgcattaa	5640
tgaatcggcc	aacgcgcggg	gagaggcggg	ttgcgtattg	ggcgtcttctc	cgcttcctcg	5700
ctcactgact	cgctgcgctc	ggtcgttcgg	ctgcggcgag	cggtatcagc	tactcaaag	5760
gcggtaatac	ggttatccac	agaatcaggg	gataacgcag	gaaagaacat	gtgagcaaaa	5820
ggccagcaaaa	aggccaggaa	ccgtaaaaag	gccgcgttgc	tggcgttttt	ccataggctc	5880
cgccccctg	acgagcatca	caaaaatcga	cgctcaagtc	agaggtggcg	aaacccgaca	5940
ggactataaa	gataaccaggc	gtttccccct	ggaagctccc	tcgtgcgctc	tcctgttccg	6000
accctgccgc	ttaccggata	cctgtccgcc	tttctccctt	cgggaagcgt	ggcgctttct	6060
catagctcac	gctgtaggta	tctcagttcg	gtgtaggtcg	ttcgctccaa	gctgggctgt	6120
gtgcacgaac	cccccgttca	gcccgaaccg	tgcgcttat	ccggtacta	tcgtcttgag	6180
tccaacccgg	taagacacga	cttatcgcca	ctggcagcag	ccactggtaa	caggattagc	6240
agagcgagg	atgtaggcgg	tgctacagag	ttcttgaagt	ggtggcctaa	ctacggctac	6300
actagaagga	cagtatttgg	tatctgcgct	ctgctgaagc	cagttacctt	cggaaaaaga	6360
gttggtagct	cttgatccgg	caaacaaacc	accgctggta	gcggtgggtt	ttttgtttgc	6420
aagcagcaga	ttacgcgcag	aaaaaaagga	tctcaagaag	atcctttgat	cttttctacg	6480

seq1ist						
gggtctgacg	ctcagtggaa	cgaaaactca	cgtaaagga	ttttggatcat	gagattatca	6540
aaaaggatct	tcacctagat	ccttttaaat	taaaaatgaa	gttttaaatc	aatctaaagt	6600
atatatgagt	aaacttggtc	tgacagttac	caatgcttaa	tcagtgaggc	acctatctca	6660
gcgatctgtc	tatttcgttc	atccatagtt	gcctgactcc	ccgtcgtgta	gataactacg	6720
atacgggagg	gcttaccatc	tggccccagt	gctgcaatga	taccgcgaga	cccacgctca	6780
ccgggtccag	atztatcagc	aataaaccag	ccagccggaa	gggccgagcg	cagaagtggg	6840
cctgcaactt	tatccgcctc	catccagtct	attaattgtt	gccgggaagc	tagagtaagt	6900
agttcgccag	ttaatagttt	gcgcaacggt	gttgccattg	ctacaggcat	cgtggtgtca	6960
cgctcgtcgt	ttggtatggc	ttcattcagc	tccggttccc	aacgatcaag	gcgagttaca	7020
tgatcccca	tgttgtgcaa	aaaagcgggt	agctccttcg	gtcctccgat	cgttgtcaga	7080
agtaagttgg	ccgcagtgtt	atcactcatg	gttatggcag	cactgcataa	ttctcttact	7140
gtcatgccat	ccgtaagatg	cttttctgtg	actggtgagt	actcaaccaa	gtcattctga	7200
gaatagtgtg	tgcggcgacc	gagttgctct	tgcccggcgt	caatacggga	taataccgcg	7260
ccacatagca	gaactttaaa	agtgtcatc	attggaaaac	gttcttcggg	gcgaaaactc	7320
tcaaggatct	taccgctgtt	gagatccagt	tcgatgtaac	ccactcgtgc	acccaactga	7380
tcttcagcat	cttttacttt	caccagcgtt	tctgggtgag	caaaaacagg	aaggcaaaat	7440
gccgcaaaaa	aggggaataag	ggcgacacgg	aaatgttgaa	tactcatact	cttccttttt	7500
caatattatt	gaagcattta	tcagggttat	tgtctcatga	gcggatacat	atttgaatgt	7560
atttagaaaa	ataaacaat	aggggttccg	cgcacatttc	cccgaaaagt	gccacctgac	7620
gtctaagaaa	ccattattat	catgacatta	acctataaaa	ataggcgtat	cacgaggccc	7680
tttcgtc						7687

<210> 7

<211> 7687

<212> DNA

<213> Artificial sequence

<220>

<223> plasmid pBE-201 for additional expression of fHBP variant 2 of *Neisseria meningitidis*

<400> 7

tcgcgcgttt	cggtgatgac	ggtgaaaacc	tctgacacat	gcagctcccg	gagacgggtca	60
cagcttgtct	gtaagcggat	gccgggagca	gacaagcccg	tcagggcgcg	tcagcgggtg	120
ttggcgggtg	tcggggctgg	cttaactatg	cggcatcaga	gcagattgta	ctgagagtgc	180
accataaatt	cgagctcgac	cgtctgaaac	ggcggcaaag	ccgttaaccc	gcgcgttgcc	240
tttaaagtgt	ggcggcgcca	tcacgcggcg	gatgggtgaa	acttgcaaac	ggtttgaaa	300
aaacagcggg	atctgtcgga	ttgttgacgg	tgcaggcata	cggttttgtg	tgcgtctgtg	360
ccttaagcgt	cggacatttc	cggcggcggc	tgtgccgtct	gaaacgcccc	gcgggggatg	420
cggctgcgtt	ttccatcgat	aagcatatct	tccggacgcg	ttcggggcgg	gttttccccg	480

seqlist

gcggccgccc	atttgtttgc	gcttatatag	tggattaaca	aaaatcagga	caaggcgacg	540
aagccgcaga	cagtacaaat	agtacggaac	cgattcactt	ggtgcttcag	caccttagag	600
aatcgttctc	tttgagctaa	ggcgaggcaa	cgccgtactg	gtttttgtta	atccactata	660
aaaaacactg	cagcaaatcg	tttaaaaaca	agcgtccttt	ttcggtcggg	cggaatacgg	720
cagggtcggg	ttccagcagg	cctttttgcc	ttgccgtttc	gatttgcgcc	atgatttttg	780
cactcggtac	gcccgtgcgc	tcctgcaaca	tcgcggcggg	tacgccgtcg	gtcaggcgca	840
gggcgttcat	catgaattcg	aacggcaaat	cttcggcagc	gacggttttg	cgttcgacgg	900
cttcactcgg	ttggccttgc	attaaggcga	ggtagtcggt	ggggtggcgg	cggcggacgg	960
tgcgctcgat	gcggtcggga	taggaaat	tgccgtgcgc	gcccgccct	atgcctaaat	1020
aatcgccgaa	ctgccagtag	ttcaaattgt	ggcggcactg	catggctggg	ttcgcaaaag	1080
ccgatgtttc	gtagtgga	aaacccgcgc	cttcagcgc	gccgtgtacc	gcgtcttcga	1140
tgtcgagggc	ggcttcgtct	tgcggaac	ctttcggcgg	cgtatgaccg	aacggcgtgt	1200
tcggttccat	cgtcagggtga	tacgcgctga	tgtgggttgc	gcccgtaggg	atcccgactt	1260
cgctgctgcc	caaggttgcc	gggtgacgca	caccgtggaa	acggatgaag	gcacgaaccc	1320
agttgacata	agcctgttcg	gttcgtaa	tgtaatgcaa	gtagcgtatg	cgctcacgca	1380
actgggtccag	aaccttgacc	gaacgcagcg	gtggtaacgg	cgcagtggcg	gttttcatgg	1440
cttggtatga	ctgtttttt	gtacagtcta	tgcctcgggc	atccaagcag	caagcgcggt	1500
acgccgtggg	tcgatgtttg	atgttatgga	gcagcaacga	tgttacgcag	cagcaacgat	1560
gttacgcagc	agggcagtcg	ccctaaaaca	aagttagggtg	gctcaagtat	gggcatcatt	1620
cgcacatgta	ggctcggccc	tgaccaagtc	aaatccatgc	gggctgctct	tgatcttttc	1680
ggtcgtgagt	tcggagacgt	agccacctac	tcccaacatc	agccggactc	cgattacctc	1740
gggaacttgc	tccgtagtaa	gacattcatc	gcgcttgctg	ccttcgacca	agaagcgggt	1800
gttggcgctc	tcgcggctta	cgttctgccc	aggtttgagc	agccgcgtag	tgagatctat	1860
atctatgatc	tcgcagtctc	cggcgagcac	cggaggcagg	gcattgccac	cgcgctcatc	1920
aatctcctca	agcatgaggc	caacgcgctt	ggtgcttatg	tgatctacgt	gcaagcagat	1980
tacggtgacg	atcccgcagt	ggctctctat	acaaagttgg	gcatacggga	agaagtgatg	2040
cactttgata	tcgaccaag	taccgccacc	taacaattcg	ttcaagccga	gatcggcttc	2100
ccggccgagg	aatgccgatt	tcttcttcca	gcaatttgat	ttgtttggag	atgccgggtt	2160
gcgaagtaaa	caaggcttcg	gccgcttcgg	aaacgttcag	gttgtgctgg	taaacttcta	2220
aggcgtat	caattgccga	caccatcgaa	tgggtcaaaa	cctttcgcgg	tatggcatga	2280
tagcgcccg	aagagagtca	attcagggtg	gtgaatgtga	aaccagtaac	gttatacgat	2340
gtcgagag	atgccggtgt	ctcttatcag	accgtttccc	gcgtggtgaa	ccaggccagc	2400
cacgtttctg	cgaaaacgcg	ggaaaaagt	gaagcggcga	tggcggagct	gaattacatt	2460
cccaaccgcg	tggcacaaca	actggcgggc	aaacagtcgt	tgctgattgg	cgttgccacc	2520

seqlist

tccagtcttg	ccctgcacgc	gccgtcgcaa	attgtcgcg	cgattaaatc	tcgcgccgat	2580
caactgggtg	ccagcgtggt	ggtgtcgatg	gtagaacgaa	gcggcgtcga	agcctgtaaa	2640
gcggcgggtg	acaatcttct	cgcgcaacgc	gtcagtgggc	tgatcattaa	ctatccgctg	2700
gatgaccagg	atgccattgc	tgtggaagct	gcctgcacta	atgttccggc	gttatttctt	2760
gatgtctctg	accagacacc	catcaacagt	attattttct	cccatgaaga	cggtacgcga	2820
ctgggcgtg	agcatctggt	cgcatgggt	caccagcaaa	tcgcgctgtt	agcgggcca	2880
ttaagtctg	tctcggcgcg	tctgcgtctg	gctggctggc	ataaatatct	cactcgcaat	2940
caaattcagc	cgatagcggg	acgggaaggc	gactggagtg	ccatgtccgg	ttttcaacaa	3000
accatgcaaa	tgctgaatga	gggcatcggt	cccactgcga	tgctggttgc	caacgatcag	3060
atggcgctg	gcgcaatgcg	cgccattacc	gagtcggggc	tgcgcggttg	tgcggatatc	3120
tcggtagtgg	gatacgacga	taccgaagac	agctcatgtt	atatcccgcc	gttaaccacc	3180
atcaaacagg	attttcgcct	gctggggcaa	accagcgtgg	accgcttgct	gcaactctct	3240
cagggccagg	cggtgaagg	caatcagctg	ttgcccgtct	cactggtgaa	aagaaaaacc	3300
accctggcgc	ccaatacgca	aaccgcctct	ccccgcgcgt	tggccgattc	attaatgcag	3360
ctggcacgac	aggtttccc	actggaaagc	gggcagtgag	cgcaacgcaa	ttaatgtaag	3420
ttagctcact	cattaggcac	aattctcatg	tttgacagct	tatcatcgac	tgacgggtgc	3480
accaatgctt	ctggcgtcag	gcagccatcg	gaagctgtgg	tatggctgtg	caggtcgtaa	3540
atcactgcat	aattcgtgtc	gctcaaggcg	cactcccgtt	ctggataatg	ttttttgcgc	3600
cgacatcata	acggttctgg	caaataattct	gaaatgagct	gttgacaatt	aatcatcggc	3660
tcgtataatg	tgtggaattg	tgagcggata	acaatttcac	acaggaaaca	gccagtccgt	3720
ttaggtgttt	tcacgagcac	ttaccaaca	aggaccatag	catatgaatc	gaactgcctt	3780
ctgctgcctt	tctctgacca	ctgcccgat	tctgaccgcc	tgacgacgcg	gaggcggcgg	3840
tgctgccgcc	gacatcggcg	cggggcttgc	cgatgcacta	accgcaccgc	tcgaccataa	3900
agacaaaagt	ttgcagtctt	tgacgctgga	tcagtccgtc	aggaaaaacg	agaaactgaa	3960
gctggcggca	caagggtcgg	agaaaactta	tggaaacggc	gacagcctca	atacgggcaa	4020
attgaagaac	gacaagggtca	gccgcttcga	ctttatccgt	caaatcgaag	tggacgggca	4080
gctcattacc	ttggagagcg	gagagttcca	aatatacaaa	caggaccact	ccgccgtcgt	4140
tgccctacag	attgaaaaaa	tcaacaaccc	cgacaaaatc	gacagcctga	taaaccaacg	4200
ctccttcctt	gtcagcgggt	tgggcggaga	acataccgcc	ttcaaccaac	tgcttgacgg	4260
caaagccgag	tatcacggca	aagcattcag	ctccgacgat	gctggcggaa	aactgaccta	4320
taccatagat	ttcgccgcca	aacagggaca	cggcaaaatc	gaacacctga	aaacaccgca	4380
gcaaaaatgtc	gagcttgccg	ccgccgaact	caaagcagat	gaaaaatcac	acgccgtcat	4440
tttgggcgac	acgcgctacg	gcagcgaaga	aaaaggcact	taccacctcg	cccttttcgg	4500
cgaccgcgcc	caagaaatcg	ccggctcggc	aaccgtgaag	ataggggaaa	aggttcacga	4560

seqlist

aatcggcatc gccggcaaac agtagtaacg ccggtgtgcg cgtcaaattc tgatatgcg	4620
cttattctgc aaaccgccag cttggctgtt ttggcgatg agagaagatt ttcagcctga	4680
tacagattaa atcagaacgc agaagcggtc tgataaaaca gaatttgcct ggcggcagta	4740
gcgcggtggt ccacactgac cccatgccga actcagaagt gaaacgccgt agcgccgatg	4800
gtagtggtgg gtctcccat gcgagagtag ggaactgcc ggcatcaaataaaaacgaaag	4860
gctcagtcga aagactgggc ctttcgtttt atctgttgtt tgtcggtgaa cgctctcctg	4920
agtaggacaa atccgccgcc cgggcgagcc ttgcggcgtt ttgttttctg ccaccgcaac	4980
tacacaagcc ggcggttttg tacgataatc ccgaatgctg cggcttctgc cgccctattt	5040
tttgaggaat ccgaaatgtc caaaaccatc atccacaccg acaaagcccc cgccgccatc	5100
ggcgcgtaca gccaaagccgt ccgagcaggc gacaccgttt acatgagcgg tcaaatacccc	5160
ctcgatcccc ccacgatgac cgtcgtcggc aacggcgatt tccgcgccga agcgcgccaa	5220
gtgttccaaa acctgcaagc cgtcgccgaa gcggcaggcg gcacgctggc cgacatcgtc	5280
aaactcaacg cctacctgac cgacttgggc aattttgccg tcttcaacga agtcatggcg	5340
gaatttatcg ccgagccctt ccccgccgc gccgcgctc gcgttgctc gctgccccaa	5400
ggcgtgcagg tcgaagccga agccgtcctc gtgaccgtc gaaacggaag cttggcgtaa	5460
tcatggtcat agctgtttcc tgtgtgaaat tgttatccgc tcacaattcc acacaacata	5520
cgagccggaa gcataaagt taaagcctgg ggtgcctaata gtagagcta actcacatta	5580
attgcgttgc gctcactgcc cgctttccag tcgggaaacc tgcgtgccga gctgcattaa	5640
tgaatcggcc aacgcgcggg gagaggcgggt ttgcgtattg ggcgctcttc cgcttcctcg	5700
ctcactgact cgctgcgctc ggtcgttcgg ctgcggcgag cggtatcagc tactcaaaag	5760
gcggtaatac ggttatccac agaatacagg gataacgcag gaaagaacat gtgagcaaaa	5820
ggccagcaaa aggccaggaa ccgtaaaaag gccgcgttgc tggcgttttt ccataggctc	5880
cgccccctg acgagcatca caaaaatcga cgctcaagtc agagggtggcg aaacccgaca	5940
ggactataaa gataccaggc gtttccccct ggaagctccc tcgtgcgctc tcctgttccg	6000
acctgcccgc ttaccggata cctgtccgcc tttctccctt cgggaagcgt ggcgctttct	6060
catagctcac gctgtaggta tctcagttcg gtgtaggtcg ttcgctccaa gctgggctgt	6120
gtgcacgaac cccccgttca gcccgaccgc tgcgccttat ccgtaacta tcgtcttgag	6180
tccaaccgga taagacacga cttatcgcca ctggcagcag cactggtaa caggattagc	6240
agagcgagggt atgtaggcgg tgctacagag ttcttgaagt ggtggcctaa ctacggctac	6300
actagaagga cagtatttgg tatctgcgct ctgctgaagc cagttacctt cgaaaaaga	6360
gttggttagct cttgatccgg caaacaacc accgctggta gcggtgggtt ttttgtttgc	6420
aagcagcaga ttacgcgcag aaaaaagga tctcaagaag atcctttgat cttttctacg	6480
gggtctgacg ctcagtggaa cgaaaactca cgtaaggga ttttggtcat gagattatca	6540
aaaaggatct tcacctagat ctttttaaat taaaaatgaa gttttaaatc aatctaaagt	6600

seqlist

atatatgagt aaacttgggtc tgacagttac caatgcttaa tcagtgaggc acctatctca	6660
gcgatctgtc tatttcgttc atccatagtt gcctgactcc ccgtcgtgta gataactacg	6720
atacgggagg gcttaccatc tggccccagt gctgcaatga taccgcgaga cccacgctca	6780
ccggctccag atttatcagc aataaaccag ccagccggaa gggccgagcg cagaagtgg	6840
cctgcaactt tatccgcctc catccagtct attaattgtt gccgggaagc tagagtaagt	6900
agttcgccag ttaatagttt gcgcaacgtt gttgccattg ctacaggcat cgtgggtgtca	6960
cgctcgtcgt ttggtatggc ttcatcagc tccggttccc aacgatcaag gcgagttaca	7020
tgatcccca tggttgcaa aaaagcgggt agtccttcg gtctccgat cgttgtcaga	7080
agtaagttgg ccgcagtgtt atcactcatg gttatggcag cactgcataa ttctcttact	7140
gtcatgccat ccgtaagatg cttttctgtg actggtgagt actcaaccaa gtcattctga	7200
gaatagtgtg tgcggcgacc gagttgctct tgcccggcgt caatacggga taataccgcg	7260
ccacatagca gaactttaaa agtgctcatc attggaaaac gttcttcggg gcgaaaactc	7320
tcaaggatct taccgctgtt gagatccagt tcgatgtaac ccactcgtgc acccaactga	7380
tcttcagcat cttttacttt caccagcgtt tctgggtgag caaaaacagg aaggcaaat	7440
gccgcaaaaa agggaataag ggcgacacgg aaatgttgaa tactcatact cttccttttt	7500
caatattatt gaagcattta tcaggggttat tgtctcatga gcggatacat atttgaatgt	7560
atttagaaaa ataaacaaat aggggttccg cgacatttc cccgaaaagt gccacctgac	7620
gtctaagaaa ccattattat catgacatta acctataaaa ataggcgtat cacgaggccc	7680
tttcgctc	7687

<210> 8

<211> 7584

<212> DNA

<213> Artificial Sequence

<220>

<223> plasmid pBE-311 for additional expression of NadA of Neisseria meningiditis

<400> 8

tcgcgcgttt cggatgatgac ggtgaaaacc tctgacacat gcagctcccg gagacgggtca	60
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg	120
ttggcgggtg tcggggctgg cttactatg cggcatcaga gcagattgta ctgagagtgc	180
accataaatt cgagctcgac cgtctgaaac ggcggcaaag ccgttaaccc gcgcgttgcc	240
tttaaagtgt ggcggcggca tcacgcggcg gatgggtgaa acttgcaaac ggtttgaaa	300
aaacagcggg atctgtcgga ttgttgagg tgcaggcata cggttttgtg tgcgtctgtg	360
ccttaagcgt cggacatttc cggcggcggc tgtgccgtct gaaacgcccg gcgggggatg	420
cggctgcgtt ttccatcgat aagcatattt tccggacgcg ttcggggcgg gttttcccgg	480
gcggccgccc atttgtttgc gcttatatag tggattaaca aaaatcagga caaggcgacg	540

				seqlist	
aagccgcaga	cagtacaaat	agtacggaac	cgattcactt	ggtgcttcag	caccttagag 600
aatcgttctc	tttgagctaa	ggcgaggcaa	cgccgtactg	gtttttgtta	atccactata 660
aaaaaactg	cagcaaatacg	tttaaaaaca	agcgtccttt	ttcggtcggg	cggaatacgg 720
cagggtcgg	ttccagcagg	cctttttgcc	ttgccgtttc	gatttgcgcc	atgattttgg 780
cactcggtag	gcccgtgcgc	tcctgcaaca	tcgcggcggg	tacgccgtcg	gtcaggcgca 840
gggcgttc	catgaattcg	aacggcaaat	cttcggcagc	gacggttttg	cgttcgacgg 900
cttcactcgg	ttggctttgc	attaaggcga	ggtagtcgtt	ggggtggcgg	cggcggacgg 960
tgcgctcgat	gcggtcggga	taggaaat	tgccgtgcgc	gcccgcgcct	atgcctaaat 1020
aatcgccgaa	ctgccagtag	ttcaaattgt	ggcggcactg	catggctgg	ttcgcaaaag 1080
ccgatgtttc	gtagtggaca	aaacccgcgc	cttcagcgc	gccgtgtacc	gcgtcttcga 1140
tgtcgagggc	ggcttcgtct	tgcggaac	cttcggcgg	cgtagaccg	aacggcgtgt 1200
tcggttccat	cgtcaggtag	tacgcgctga	tgtgggttgc	gcccgtaggg	atcccgaactt 1260
cgctgctgcc	caaggttgcc	gggtgacgca	caccgtggaa	acggatgaag	gcacgaaccc 1320
agttgacata	agcctgttcg	gttcgtaa	tgtaatgcaa	gtagcgtatg	cgctcacgca 1380
actggtccag	aaccttgacc	gaacgcagcg	gtggtaacgg	cgagtgggcg	gttttcattg 1440
cttgttatga	ctgttttttt	gtacagtcta	tgcctcgggc	atccaagcag	caagcgcgtt 1500
acgccgtggg	tcgatgtttg	atgttatgga	gcagcaacga	tgttacgcag	cagcaacgat 1560
gttacgcagc	agggcagtcg	ccctaaaaca	aagttagggtg	gctcaagtat	gggcattcatt 1620
cgcacatgta	ggctcgggcc	tgaccaagtc	aaatccatgc	gggctgctct	tgatcttttc 1680
ggtcgtgagt	tcggagacgt	agccacctac	tcccaacatc	agccggactc	cgattacctc 1740
gggaacttgc	tccgtagtaa	gacattcatc	gcgcttgctg	ccttcgacca	agaagcggtt 1800
gttggcgctc	tcgcggctta	cgttctgccc	aggtttgagc	agccgcgtag	tgagatctat 1860
atctatgatc	tcgcagtctc	cggcgagcac	cggaggcagg	gcattgccac	cgcgctcatc 1920
aatctcctca	agcatgaggc	caacgcgctt	ggtgcttatg	tgatctacgt	gcaagcagat 1980
tacggtgacg	atcccgcagt	ggctctctat	acaaagttag	gcatacggga	agaagtgatg 2040
cactttgata	tcgacccaag	taccgccacc	taacaattcg	ttcaagccga	gatcggcttc 2100
ccggccgcgg	tcggactttc	agataatctt	tgaatattgc	tgttgttcta	aggtctagat 2160
tcccgcctgc	gcgggaatga	cgaatccatc	cgcacggaaa	cctgcaccac	gtcattccca 2220
cgaaccaca	tcccgtcatt	accacgaaag	tgggaatcta	ggacgcaggg	ttaagaaaac 2280
ctacatccc	tcattcctca	aaaacagaaa	acaaaaatca	gaaacctaaa	atcccgtcat 2340
tcccgcgcag	gcgggaatcc	agtccgttca	gtttcggctg	tttccgataa	attcctgctg 2400
cttttcattt	ctagattccc	actttcgtgg	gaatgacggc	ggaagggttt	tggttttttc 2460
cgataaattc	ttgaggcatt	gaaattctag	attccgcct	gcgcgggaat	gacgaatcca 2520
tccgtacgga	aacctgcacc	acgtcattcc	taagaacctc	catcccgtca	ttccctcaaa 2580

seq1list						
aacagaaaac	caaaatcaga	aacctaataat	cccgtcattc	ccgcgcaggc	gggaatccag	2640
tccgttcagt	ttcggtcatt	tccgataaat	tcctgctgct	tttcatttct	agattcccac	2700
tttcgtggga	atgacggcgg	aagggttttg	gttttttccg	ataaattctt	gaggcattga	2760
aattctagat	tcccgcctgc	gcgggaatga	cggctgtaga	tgcccgatgg	tctttatagc	2820
ggattaacaa	aaatcaggac	aaggcgacga	agccgcagac	agtacagata	gtacggaacc	2880
gattcacttg	gtgcttcagc	accttagaga	atcgttctct	ttgagctaag	gcgaggcaac	2940
gccgtacttg	tttttgtaa	tccactataa	agtgccgcgt	gtgttttttt	atggcgtttt	3000
aaaaagccga	gactgcatcc	gggcagcagc	gcatcggttc	gcacgaggtc	tgcgcttgaa	3060
ttgtgttgta	gaaacacaac	gtttttgaaa	aaataagcta	ttgttttata	tcaaaatata	3120
atcattttta	aaataaagg	tgcggcattt	atcagatatt	tgttctgaaa	aatggttttt	3180
tgcggggggg	ggggtataat	tgaagacgta	tcgggtgttt	gcccgatgtt	tttaggtttt	3240
tatcaaattt	acaaaaggaa	gccgatcata	tgaaacactt	tccatccaaa	gtactgacca	3300
cagccatcct	tgccactttc	tgtagcggcg	cactggcagc	cacaaacgac	gacgatgtta	3360
aaaaagctgc	cactgtggcc	attgctgctg	cctacaacaa	tgccaagaa	atcaacgggt	3420
tcaaagctgg	agagaccatc	tacgacattg	atgaagacgg	cacaattacc	aaaaaagacg	3480
caactgcagc	cgatgttgaa	gccgacgact	ttaaaggctc	gggtctgaaa	aaagtcgtga	3540
ctaacctgac	caaaaccgtc	aatgaaaaca	aacaaaacgt	cgatgccaaa	gtaaaagctg	3600
cagaatctga	aatagaaaag	ttaacaacca	agttagcaga	cactgatgcc	gcttttagcag	3660
atactgatgc	cgctctggat	gcaaccacca	acgccttgaa	taaattggga	gaaaatataa	3720
cgacatttgc	tgaagagact	aagacaaata	tcgtaaaaaat	tgatgaaaaa	ttagaagccg	3780
tggttgatac	cgctcgacaag	catgccgaag	cattcaacga	tatcgccgat	tcattggatg	3840
aaaccaacac	taaggcagac	gaagccgtca	aaaccgccaa	tgaagccaaa	cagacggccg	3900
aagaaaccaa	acaaaacgtc	gatgccaaag	taaaagctgc	agaaactgca	gcaggcaaag	3960
ccgaagctgc	cgctggcaca	gctaatactg	cagccgacaa	ggccgaagct	gtcgctgcaa	4020
aagttaccga	catcaaagct	gatatcgcta	cgaacaaaga	taatattgct	aaaaaagcaa	4080
acagtgccga	cggtgtacacc	agagaagagt	ctgacagcaa	atttgtcaga	attgatggtc	4140
tgaacgctac	taccgaaaaa	ttggacacac	gcttggcttc	tgctgaaaaa	tccattgccg	4200
atcacgatac	tcgcctgaac	ggtttgata	aaacagtgtc	agacctgcgc	aaagaaaccc	4260
gccaaggcct	tgcaaacaa	gccgcgtct	ccggtctgtt	ccaaccttac	aacgtgggtc	4320
ggttcaatgt	aacggctgca	gtcggcggct	acaaatccga	atcggcagtc	gccatcggtg	4380
ccggcttccg	ctttaccgaa	aactttgccg	ccaaagcagg	cgtaggcagtc	ggcacttcgt	4440
ccggttcttc	cgcagcctac	catgtcggcg	tcaattacga	gtggtaacgc	cggtgtatat	4500
cggggcggtg	aagcggatag	ctttgttttt	gacggctcgc	cttcattctt	tgattgcaat	4560
ctgactgcc	atctgcttca	gccccaaaca	aaaatccgga	tacggaagaa	aaacggcaat	4620

seqlist						
aaagacagca	aataccgtct	gaaagatttt	cagacggtat	ttcgcatttt	tggcttggtt	4680
tgcacatata	gtgagacctt	tgcaaaaata	gtctgttaac	gaaatttgac	gcataaaaat	4740
gcgccccaaaa	attttcaatt	gcctaaaacc	ttcctaatat	tgagcaaaaa	gtaggaaaaa	4800
tcagaaaagt	tttgcatttt	gaaaatgaga	ttgagcataa	aatttttagta	acctatgtta	4860
ttgcaaaggt	ctcgaattgt	cattccccacg	caggcgggaa	tctagtctgg	aatgctgcgg	4920
cttctgccgc	cctatTTTTT	gaggaatccg	aaatgtccaa	aaccatcatc	cacaccgaca	4980
aagccccgc	cgccatcggc	gcgtacagcc	aagccgtccg	agcaggcgac	accgtttaca	5040
tgagcgggtca	aatccccctc	gatccccgca	cgatgaccgt	cgtcggcaac	ggcgatttcc	5100
gcgccgaagc	gcgccaagt	ttccaaaacc	tgcaagccgt	cgccgaagcg	gcaggcggca	5160
cgctggccga	catcgtcaaa	ctcaacgcct	acctgaccga	cttgggcaat	tttgccgtct	5220
tcaacgaagt	catggcgga	tttatcgccg	agcccttccc	cgcccgccg	gccgtcggcg	5280
ttgcctcgct	gccccaaaggc	gtgcaggctg	aagccgaagc	cgctctcgtg	accgtctgaa	5340
acggaagctt	ggcgtaatca	tggcatagc	tgtttcctgt	gtgaaattgt	tatccgctca	5400
caattccaca	caacatacga	gccggaagca	taaagtgtaa	agcctggggg	gcctaattgag	5460
tgagctaact	cacattaatt	gcgttgcgct	cactgccccg	tttccagtcg	ggaaacctgt	5520
cgtgccagct	gcattaatga	atcggccaac	gcgcggggag	aggcggtttg	cgtattgggc	5580
gctcttccgc	ttcctcgtc	actgactcgc	tgcgctcggt	cgttcggctg	cggcgagcgg	5640
tatcagctca	ctcaaaggcg	gtaatacgg	tatccacaga	atcaggggat	aacgcaggaa	5700
agaacatgtg	agcaaaaggc	cagcaaaagg	ccaggaaccg	taaaaaggcc	gcgttgctgg	5760
cgtttttcca	taggtctccg	ccccctgacg	agcatcaca	aaatcgacgc	tcaagtcaga	5820
ggtggcgaaa	cccgacagga	ctataaagat	accaggcggt	tccccctgga	agctccctcg	5880
tgcgctctcc	tgttccgacc	ctgccgctta	ccggatacct	gtccgccttt	ctcccttcgg	5940
gaagcgtggc	gctttctcat	agctcacgct	gtaggtatct	cagttcgggtg	taggtcggtc	6000
gctccaagct	gggctgtgtg	cacgaacccc	ccgttcagcc	cgaccgctgc	gccttatccg	6060
gtaactatcg	tcttgagtcc	aacccggtaa	gacacgactt	atcgccactg	gcagcagcca	6120
ctggtaacag	gattagcaga	gcgaggtatg	taggcgggtg	tacagagttc	ttgaagtgg	6180
ggcctaacta	cggctacact	agaaggacag	tatttggtat	ctgcgctctg	ctgaagccag	6240
ttaccttcgg	aaaaagagtt	ggtagctctt	gatccggcaa	acaaaccacc	gctggtagcg	6300
gtggtttttt	tgtttgcaag	cagcagatta	cgcgcagaaa	aaaaggatct	caagaagatc	6360
ctttgatctt	ttctacgggg	tctgacgctc	agtggaacga	aaactcacgt	taagggattt	6420
tggatcatgag	attatcaaaa	aggatcttca	cctagatcct	tttaaattaa	aaatgaagtt	6480
ttaaataaat	ctaaagtata	tatgagtaaa	cttggtctga	cagttaccaa	tgcttaatca	6540
gtgaggcacc	tatctcagcg	atctgtctat	ttcgttcatc	catagttgcc	tgactccccg	6600
tcgtgtagat	aactacgata	cgggaggggt	taccatctgg	ccccagtgct	gcaatgatac	6660

seqlist						
cgcgagaccc	acgctcaccg	gctccagatt	tatcagcaat	aaaccagcca	gccggaaggg	6720
ccgagcgcag	aagtgggtcct	gcaactttat	ccgcctccat	ccagtctatt	aattgttgcc	6780
gggaagctag	agtaagtagt	tcgccagtta	atagtttgcg	caacgttggt	gccattgcta	6840
caggcatcgt	ggtgtcacgc	tcgtcgtttg	gtatggcttc	attcagctcc	ggttcccaac	6900
gatcaaggcg	agttacatga	tcccccatgt	tgtgcaaaaa	agcggtttagc	tccttcggtc	6960
ctccgatcgt	tgtcagaagt	aagttggccg	cagtgttatc	actcatgggt	atggcagcac	7020
tgcataattc	tcttactgtc	atgccatccg	taagatgctt	ttctgtgact	ggtgagtact	7080
caaccaagtc	attctgagaa	tagtgtatgc	ggcgaccgag	ttgctcttgc	ccggcgtcaa	7140
tacgggataa	taccgcgcca	catagcagaa	ctttaaaagt	gctcatcatt	ggaaaacgtt	7200
cttcggggcg	aaaactctca	aggatcttac	cgctgttgag	atccagttcg	atgtaacca	7260
ctcgtgcacc	caactgatct	tcagcatctt	ttactttcac	cagcgtttct	gggtgagcaa	7320
aaacaggaag	gcaaaatgcc	gcaaaaaagg	gaataagggc	gacacggaaa	tgttgaatac	7380
tcatactctt	cctttttcaa	tattattgaa	gcatttatca	gggttattgt	ctcatgagcg	7440
gatacatatt	tgaatgtatt	tagaaaaata	aacaaatagg	ggttccgcgc	acatttcccc	7500
gaaaagtgcc	acctgacgtc	taagaaacca	ttattatcat	gacattaacc	tataaaaata	7560
ggcgtatcac	gaggcccttt	cgtc				7584

<210> 9
 <211> 5759
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> plasmid pBE-501 for knockout of lgtA gene of Neisseria meningitidis by replacement with zeomycin gene

<400> 9		
cttccgcttc	ctcgtctact gactcgctgc gctcggctcgt tcggctgcgg cgagcggtat	60
cagctcactc	aaaggcggtg atacggttat ccacagaatc aggggataac gcaggaaaga	120
acatgtgagc	aaaaggccag caaaaggcca ggaaccgtaa aaaggccgcg ttgctggcgt	180
ttttccatag	gctccgcccc cctgacgagc atcacaaaaa tcgacgctca agtcagaggt	240
ggcgaaaccc	gacaggacta taaagatacc aggcgtttcc ccctggaagc tccctcgtgc	300
gctctcctgt	tccgaccctg ccgcttaccg gatacctgtc cgcctttctc ccttcgggaa	360
gcgtggcgct	ttctcatagc tcacgctgta ggtatctcag ttcgggtgtag gtcgttcgct	420
ccaagctggg	ctgtgtgcac gaaccccccg ttcagcccga ccgctgcgcc ttatccggta	480
actatcgtct	tgagtccaac ccggttaagac acgacttatc gccactggca gcagccactg	540
gtaacaggat	tagcagagcg aggtatgtag gcggtgctac agagtctctg aagtgggtggc	600
ctaactacgg	ctacactaga agaacagtat ttgggtatctg cgctctgctg aagccagtta	660
ccttcggaaa	aagagttggg agctcttgat ccggcaaaca aaccaccgct ggtagcgggtg	720
gtttttttgt	ttgcaagcag cagattacgc gcagaaaaaa aggatctcaa gaagatcctt	780

seqlist

tgatcttttc	tacggggtct	gacgctcagt	ggaacgaaaa	ctcacgttaa	gggatttttg	840
tcatgagaca	ataaccctga	taaatgcttc	aataatattg	aaaaaggaag	agtatgagta	900
ttcaacattt	ccgtgtcgcc	cttattccct	tttttgcggc	attttgcctt	cctgtttttg	960
ctcaccaga	aacgctggtg	aaagtaaaag	atgctgaaga	tcagttgggt	gcacgagtgg	1020
gttacatcga	actggatctc	aacagcggta	agatccttga	gagttttcgc	cccgaagaac	1080
gttttccaat	gatgagcact	tttaaagttc	tgctatgtgg	cgcggtatta	tcccgtattg	1140
acgccgggca	agagcaactc	ggtcgccgca	tacactattc	tcagaatgac	ttggttgagt	1200
actcaccagt	cacagaaaaag	catcttacgg	atggcatgac	agtaagagaa	ttatgcagtg	1260
ctgccataac	catgagtgat	aacactgcgg	ccaacttact	tctgacaacg	atcggaggac	1320
cgaaggagct	aaccgctttt	ttgcacaaca	tgggggatca	tgtaactcgc	cttgatcggt	1380
gggaaccgga	gctgaatgaa	gccataccaa	acgacgagcg	tgacaccacg	atgcctgtag	1440
caatggcaac	aacgttgcg	aaactattaa	ctggcgaact	acttactcta	gcttccccgc	1500
aacaattaat	agactggatg	gaggcggata	aagttgcagg	accacttctg	cgctcggccc	1560
ttccggctgg	ctggtttatt	gctgataaat	ctggagccgg	tgagcgtggg	tctcgcggta	1620
tcattgcagc	actggggcca	gatggtaagc	cctcccgtat	cgtagttatc	tacacgacgg	1680
ggagtcaggc	aactatggat	gaacgaaata	gacagatcgc	tgagataggt	gcctcactga	1740
ttaagcattg	gtaactgtca	gaccaagttt	actcatatat	acttttagatt	gatttaaaac	1800
ttcattttta	atttaaaagg	atctaggtga	agatcctttt	tgataatctc	atgagcggat	1860
acatatttga	atgtatttag	aaaaataaac	aataggggt	tccgcgcaca	tttccccgaa	1920
aagtgccacc	tgatgcggtg	tgaaataaccg	cacagatgcg	taaggagaaa	ataccgcatc	1980
aggaaattgt	aagcgtaaat	aattcagaag	aactcgtcaa	gaaggcgata	gaaggcgatg	2040
cgctgcgaat	cgggagcggc	gataccgtaa	agcacgagga	agcggtcagc	ccattcgccg	2100
ccaagctctt	cagcaatatc	acgggtagcc	aacgctatgt	cctgatagcg	gtccgccaca	2160
cccagccggc	cacagtcgat	gaatccagaa	aagcggccat	tttccaccat	gatattcggc	2220
aagcaggcat	cgccatgggt	cacgacgaga	tcctcgccgt	cgggcatgct	cgcttgagc	2280
ctggcgaaca	gttcggctgg	cgcgagcccc	tgatgctctt	cgtccagatc	atcctgatcg	2340
acaagaccgg	cttccatccg	agtacgtgct	cgctcgatgc	gatgtttcgc	ttggtggtcg	2400
aatgggcagg	tagccggatc	aagcgtatgc	agccgccgca	ttgcatcagc	catgatggat	2460
actttctcgg	caggagcaag	gtgagatgac	aggagatcct	gccccggcac	ttcgcccaat	2520
agcagccagt	cccttccccg	ttcagtgaca	acgtcgagca	cagctgcgca	aggaacgccc	2580
gtcgtggcca	gccacgatag	ccgcgctgcc	tcgtcttgca	gttcattcag	ggcaccggac	2640
aggtcggtct	tgacaaaaag	aaccgggcgc	ccctgcgctg	acagccggaa	cacggcggca	2700
tcagagcagc	cgattgtctg	ttgtgcccag	tcatagccga	atagcctctc	caccaagcg	2760
gccggagaac	ctgcgtgcaa	tccatcttgt	tcaatcatgc	gaaacgatcc	tcctcctgtc	2820

seqlist

tcttgatcag agcttgatcc cctgcgccat cagatccttg gcggcaagaa agccatccag	2880
tttactttgc agggcttccc aaccttacca gagggcgccc cagctggcaa ttccggttcg	2940
cttgctgtcc ataaaaaccgc ccagtctagc tatcgccatg taagcccact gcaagctacc	3000
tgcttttctct ttgcgcttgc gttttccctt gtccagatag cccagtagct gacattcatc	3060
cggggtcagc accgtttctg cggactggct ttctacgtga aaaggatcta ggtgaagatc	3120
ctttttgata atctcatgcc tgacatttat attccccaga acatcagggtt aatggcgttt	3180
ttgatgtcat tttcgcggtg gctgagatca gccacttctt ccccgataac ggagaccggc	3240
acactggcca tatcgggtggc catcatgcgc cagctttcat ccccgatatg caccaccggg	3300
taaagttcac gggagacttt atctgacagc agacgtgcac tggccagggg gatcaccatc	3360
cgtcgccccg gcgtgtcaat aatatcactc tgtacatcca caaacagacg ataacggctc	3420
tctcttttat aggtgtaaac cttaaaactgc cgtacgtata ggctgcgcaa ctggtgggaa	3480
gggcgatcgg tgcgggcctc ttcgctatta cgccagctgg cgaaaggggg atgtgctgca	3540
aggcgattaa gttgggtaac gccagggttt tcccagtcac gacgttgtaa aacgacggcc	3600
agtgaattgt aatacgactc actatagggc gaattgaatt tagcggccgc gaattcgccc	3660
ttgcgtcgac cgtctgaaac gggggcgagt aaccgttgta cagtccaaat gccgtctgaa	3720
gccttcagac ggcacgtgc ctatcgggag aataaattgc agcctttagt cagcgtattg	3780
atttgcgcct acaacgtaga aaaatatttc gcccaatcat tagccgccgt cgtgaatcaa	3840
acttggcgca acttggatat tttgattgtc gatgacggct cgacggacgg tacgcttgcc	3900
attgcccagc gtttccaaga acaggacggc cgcattccgca tcctcgcgca gccgcgcaat	3960
tccggtctga ttccctcttt aaacatcggg ctggatgaat tggcaaagtc gggggggggg	4020
ggggaatata ttgcgcgatc gctagctcga gcacgtgttg acaattaatc atcggcatag	4080
tatatcggca tagtataata cgacaagggt aggaactaaa ccatggccaa gttgaccagt	4140
gccgttccgg tgctcaccgc gcgcgacgtc gccggagcgg tcgagttctg gaccgaccgg	4200
ctcgggttct cccgggactt cgtggaggac gacttcgccg gtgtgggtccg ggacgacgtg	4260
accctgttca tcagcgcggt ccaggaccag gtggtgccgg acaacaccct ggcctgggtg	4320
tgggtgcgcg gcctggacga gctgtacgcc gagtggtcgg aggtcgtgtc cacgaacttc	4380
cgggacgcct ccgggccggc catgaccgag atcggcgagc agccgtgggg gcgggagttc	4440
gccctgcgcg acccggccgg caactgcgtg cacttcgtgg ccgaggagca ggactgagaa	4500
ttcccgggga tcctctagag tcgacctgca ggcattgcaag cttggcactg gccgtcgttt	4560
tacaacgtcg tgactgggaa aaccctggcg ttaccaact taatcgcctt gcagcacatc	4620
cccctttcgc cagcgcgcac cgatgcagac gatattgccg ccccgactg gattgagaaa	4680
atcgtgggtg agatggaaaa agaccgcagc atcatcgca tgggtgcgtg gctggaagtt	4740
ttgtcggaag aaaaggacgg caaccggctg gcgcggcacc acgaacacgg caaaaattgg	4800
aaaaaaccga cccgacacga agacattgcc gactttttcc ctttcggcaa ccccatacac	4860

seqlist

aacaacacga	tgattatgag	gcgcagcgtc	attgacggcg	gtttgcgta	caacaccgag	4920
cgggattggg	cggaagatta	ccaattttgg	tacgatgtca	gcaaattggg	caggctggct	4980
tattatcccc	aagccttgg	caaataccgc	cttcacgcca	atcaggtttc	atccaaatac	5040
agcatccgcc	aacacgaaat	cgcgcaaggc	atccaaaaaa	ccgccagaaa	cgattttttg	5100
cagtctatgg	gttttaaaac	ccggttcgac	agccttgaat	accgccaaat	aaaagcagta	5160
gcgtatgaat	tgctggagaa	acatttgccg	gaagaagatt	ttgaacgcgc	ccgccggttt	5220
ttgtaccaat	gcttcaaacg	gacggacacg	ctgcccgcg	gcgcgtggct	ggattttgcg	5280
gcagacggca	ggatgcggcg	gctgtttacc	ttgaggcaat	acttcggcat	tttgcaccga	5340
ttgctgaaaa	accgttgaaa	aacgccgctt	tatccaacag	acaaaaaaca	ggataaatta	5400
tgcaaaacca	cgttatcagc	ttagcttccg	ccgcagaacg	cagggcgccc	gtttcagacg	5460
gtcgaaaggg	cgaattcggt	taaacctgca	ggactagtcc	ctttagttag	ggttaattct	5520
gagcttggcg	taatcatggt	catagctggt	tcctgtgtga	aattgttatc	cgctcacaat	5580
tccacacaac	atacgagccg	gaagcataaa	gtgtaaagcc	tggggtgcct	aatgagttag	5640
ctaactcaca	ttaattgcgt	tgcgctcact	gcccgccttc	cagtcgggaa	acctgtcgtg	5700
ccagctgcat	taatgaatcg	gccaacgcgc	ggggagaggc	ggtttgcgta	ttgggcgct	5759